Richard Bucala, MD, PhD
Research & Publications
Biography
News
Locations
Research Summary
The goal of our studies is to understand the mechanisms by which host immunity converts from a protective response to one producing disease. We focus significant attention on the role of host cytokine, MIF, which we cloned in 1993, in the development of the inflammatory complications of different infections and autoimmune diseases. MIF is an endogenous counter-regulator of the immunosuppressive action of glucocorticoids and its role in human disease has been underscored by the discovery of functional promoter polymorphisms in the human gene, which are associated with different inflammatory and infectious disorders. Our studies of MIF encompass structure-function, immunological, and pharmacologic targeting studies. We also are pursuing the genetic epidemiology of MIF; for example, we direct studies of malaria and tuberculosis susceptibility in sub-Saharan Africa, and we are investigating the role of MIF alleles in different autoimmune and infectious diseases. A separate line of inquiry is directed at the fibrocyte, which is a novel circulating leukocyte that contributes to the immunopathogenesis of fibrosing disorders.
Specialized Terms: Mechanisms by which host immunity converts from a protective response to one producing disease and tissue pathology; Emergence of steroid resistance; Biochemical, biological, and genetic characterization of the MIF cytokine family; MIF's role in malaria and global infectious diseases; Pharmacologic immuniomodulation of the MIF pathway; Role of fibrocytes in different systemic fibroses
Extensive Research Description
We seek to understand the mechanisms by which host immunity converts from a protective response to one producing disease and tissue pathology. A main focus of our efforts is on the cytokine, MIF, which we cloned from the pituitary gland and discovered to counter-regulate the immunosuppressive actions of glucocorticoids. MIF production is tightly linked to the expression of many autoimmune and inflammatory diseases, and anti-MIF strategies are effective in reducing immunopathology in many experimental models of disease.An important goal for us is to elucidate the emergence of steroid resistance, aclinical problem that restricts the effective treatment of autoimmune diseases such as rheumatoid arthritis.
Our laboratory investigations encompass the biochemical, biological, andgenetic characterization of MIF, and we remain focused on understanding MIF's role in physiology and pathology. We have uncovered a unique action for MIF in sustaining inflammatory signal transduction, a pathway that impacts on the proliferation and long-term activation of many cell types. Our studies support an important role for MIF in inhibiting p53-dependent growth arrest, which isan action that sustains the pro-inflammatory phenotype of monocytes/macrophages. We have discovered functionally important polymorphisms in the promoter for human MIFthat are associated with the severity immunologic diseases such as rheumatoid arthritis, asthma, and SLE.Additionally, they play a role in the inflammatory pathogenesis of malignancies such as prostate cancer and in the neurodevelopmental disorder, autism.
We initiated studies of MIF's role in the development of severe malarial anemia, which is the proximate cause of death in the nearly 1.5 million deaths that occur annually from malaria. We conduct clinical studies in Zambia to examine the clinical frequency of different MIF genetic polymorphisms in an effort to understand why severe malaria develops in certain children. Additional studiesare underway in to examine the role of MIF in Leishmaniasis and in tuberculosis. Population stratification of high and low expression forms of the MIF gene appear to account for differential susceptibility to malaria or autoimmunity.
In a separate line of investigation, we study the biology of fibrocytes,a blood-borne cell with inflammatory and fibrogenic properties. We first characterized these cells in studies of wound repair and granuloma formation, and we are exploring their role in different systemic fibroses.
Coauthors
Research Interests
Africa; Epidemiology; Macrophage Migration-Inhibitory Factors; Malaria; Pathology; Public Health; Rheumatology; Stem Cells; Global Health; Communicable Diseases, Emerging; Infectious Disease Medicine
Public Health Interests
Clinical Trials; Emerging Infectious Diseases; Genetics, Genomics, Epigenetics; Immunology; Infectious Diseases; Parasitology
Selected Publications
- MIF is a Common Genetic Determinant of COVID-19 Symptomatic Infection and SeverityShin JJ, Fan W, Par-Young J, Piecychna M, Leng L, Israni-Winger K, Qing H, Gu J, Zhao H, Schulz WL, Unlu S, Kuster J, Young G, Liu J, Ko AI, Garcia A, Sauler M, Wisnewski AV, Young L, Orduña A, Wang A, Klementina O, Garcia AB, Hegyi P, Armstrong ME, Mitchell P, Ordiz DB, Garami A, Kang I, Bucala R. MIF is a Common Genetic Determinant of COVID-19 Symptomatic Infection and Severity. QJM 2022, 116: hcac234. PMID: 36222594, PMCID: PMC9620729, DOI: 10.1093/qjmed/hcac234.
- Extracellular Macrophage Migration Inhibitory Factor (MIF) Downregulates Adipose Hormone-Sensitive Lipase (HSL) and Contributes to ObesityChen L, Li L, Cui D, Huang Y, Tong H, Zabihi H, Wang S, Qi Y, Lakowski T, Leng L, Liu S, Wu H, Young L, Bucala R, Qi D. Extracellular Macrophage Migration Inhibitory Factor (MIF) Downregulates Adipose Hormone-Sensitive Lipase (HSL) and Contributes to Obesity. Molecular Metabolism 2023, 101834. PMID: 37935315, DOI: 10.1016/j.molmet.2023.101834.
- Immunology for the Rheumatologist: A&R introduces a new problem‐based immunology review series with great educational potentialBucala R, Solomon D. Immunology for the Rheumatologist: A&R introduces a new problem‐based immunology review series with great educational potential. Arthritis & Rheumatology 2023 PMID: 37655656, DOI: 10.1002/art.42688.
- Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammationPekayvaz K, Gold C, Hoseinpour P, Engel A, Martinez-Navarro A, Eivers L, Coletti R, Joppich M, Dionísio F, Kaiser R, Tomas L, Janjic A, Knott M, Mehari F, Polewka V, Kirschner M, Boda A, Nicolai L, Schulz H, Titova A, Kilani B, Lorenz M, Fingerle-Rowson G, Bucala R, Enard W, Zimmer R, Weber C, Libby P, Schulz C, Massberg S, Stark K. Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation. Immunity 2023 PMID: 37652021, DOI: 10.1016/j.immuni.2023.08.002.
- Macrophage migration inhibitory factor (MIF) and its homolog D-dopachrome tautomerase (D-DT) are significant promotors of UVB- but not chemically induced non-melanoma skin cancerHuth S, Huth L, Heise R, Marquardt Y, Lopopolo L, Piecychna M, Boor P, Fingerle-Rowson G, Kapurniotu A, Yazdi A, Bucala R, Bernhagen J, Baron J. Macrophage migration inhibitory factor (MIF) and its homolog D-dopachrome tautomerase (D-DT) are significant promotors of UVB- but not chemically induced non-melanoma skin cancer. Scientific Reports 2023, 13: 11611. PMID: 37464010, PMCID: PMC10354066, DOI: 10.1038/s41598-023-38748-9.
- The SNP rs755622 is associated with immune activation in glioblastomaAlban T, Grabowski M, Otvos B, Bayik D, Wang W, Zalavadia A, Makarav V, Troike K, McGraw M, Rabljenovic A, Lauko A, Neumann C, Roversi G, Waite K, Cioffi G, Patil N, Tran T, McCortney K, Steffens A, Diaz-Montero C, Brown J, Egan K, Horbinski C, Barnholtz-Sloan J, Rajappa P, Vogelbaum M, Bucala R, Chan T, Ahluwalia M, Lathia J. The SNP rs755622 is associated with immune activation in glioblastoma. JCI Insight 2023, 8: e160024. PMID: 37252795, PMCID: PMC10371339, DOI: 10.1172/jci.insight.160024.
- Urothelial Oxidative Stress and ERK Activation Mediate HMGB1-Induced Bladder PainYe S, Mahmood D, Ma F, Leng L, Bucala R, Vera P. Urothelial Oxidative Stress and ERK Activation Mediate HMGB1-Induced Bladder Pain. Cells 2023, 12: 1440. PMCID: PMC10217556, DOI: 10.3390/cells12101440.
- Urothelial Oxidative Stress and ERK Activation Mediate HMGB1-Induced Bladder PainYe S, Mahmood D, Ma F, Leng L, Bucala R, Vera P. Urothelial Oxidative Stress and ERK Activation Mediate HMGB1-Induced Bladder Pain. Cells 2023, 12: 1440. PMID: 37408274, PMCID: PMC10217556, DOI: 10.3390/cells12101440.
- A pref-1-controlled non-inflammatory mechanism of insulin resistanceHuang Y, Cui D, Chen L, Tong H, Wu H, Muller G, Qi Y, Wang S, Xu J, Gao X, Fifield K, Wang L, Xia Z, Vanderluit J, Liu S, Leng L, Sun G, McGuire J, Young L, Bucala R, Qi D. A pref-1-controlled non-inflammatory mechanism of insulin resistance. IScience 2023, 26: 106923. PMCID: PMC10239698, DOI: 10.1016/j.isci.2023.106923.
- A pref-1-controlled non-inflammatory mechanism of insulin resistanceHuang Y, Cui D, Chen L, Tong H, Wu H, Muller G, Qi Y, Wang S, Xu J, Gao X, Fifield K, Wang L, Xia Z, Vanderluit J, Liu S, Leng L, Sun G, McGuire J, Young L, Bucala R, Qi D. A pref-1-controlled non-inflammatory mechanism of insulin resistance. IScience 2023, 26: 106923. PMID: 37283810, PMCID: PMC10239698, DOI: 10.1016/j.isci.2023.106923.
- Modulating IL-1β and its receptors shapes spike-specific CD4 +T cell responses to mRNA vaccinationPark H, Shin M, Shin J, Kim H, Kang B, Par-Young J, Unlu S, Afinogenova Y, Catanzaro J, Young J, Kim M, Lee S, You S, Racke M, Bucala R, Kang I. Modulating IL-1β and its receptors shapes spike-specific CD4 +T cell responses to mRNA vaccination. The Journal Of Immunology 2023, 210: 159.20-159.20. DOI: 10.4049/jimmunol.210.supp.159.20.
- Reflections for the 50th Anniversary of The Journal of Rheumatology: The Past, Present, and Future of RheumatologyMasi A, Bucala R. Reflections for the 50th Anniversary of The Journal of Rheumatology: The Past, Present, and Future of Rheumatology. The Journal Of Rheumatology 2023, 50: 144-146. PMID: 36587952, DOI: 10.3899/jrheum.220588.
- How to build a game-changing malaria vaccineBucala R. How to build a game-changing malaria vaccine. 2023 DOI: 10.33424/futurum362.
- Correction to: Clinical features and high-risk indicators of central nervous system involvement in primary Sjögren’s syndromeFan W, Par-Young J, Li K, Zhang Y, Xiao P, Hua L, Leng L, Chen X, Bucala R. Correction to: Clinical features and high-risk indicators of central nervous system involvement in primary Sjögren’s syndrome. Clinical Rheumatology 2022, 42: 643-643. PMID: 36565380, PMCID: PMC9873696, DOI: 10.1007/s10067-022-06488-2.
- Clinical features and high-risk indicators of central nervous system involvement in primary Sjögren’s syndromeFan W, Par-Young J, Li K, Zhang Y, Xiao P, Hua L, Leng L, Chen X, Bucala R. Clinical features and high-risk indicators of central nervous system involvement in primary Sjögren’s syndrome. Clinical Rheumatology 2022, 42: 443-451. PMID: 36401063, PMCID: PMC9873757, DOI: 10.1007/s10067-022-06448-w.
- CD74 as a regulator of transcription in normal B cellsDavid K, Friedlander G, Pellegrino B, Radomir L, Lewinsky H, Leng L, Bucala R, Becker-Herman S, Shachar I. CD74 as a regulator of transcription in normal B cells. Cell Reports 2022, 41: 111572. PMID: 36323260, DOI: 10.1016/j.celrep.2022.111572.
- Macrophage Migration Inhibitory Factor (MIF) Promotes Increased Proportions of the Highly Permissive Th17-like Cell Profile during HIV InfectionTrifone C, Baquero L, Czernikier A, Benencio P, Leng L, Laufer N, Quiroga MF, Bucala R, Ghiglione Y, Turk G. Macrophage Migration Inhibitory Factor (MIF) Promotes Increased Proportions of the Highly Permissive Th17-like Cell Profile during HIV Infection. Viruses 2022, 14: 2218. PMID: 36298774, PMCID: PMC9611675, DOI: 10.3390/v14102218.
- Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody DeficiencyShin JJ, Par-Young J, Unlu S, McNamara A, Park HJ, Shin MS, Gee RJ, Doyle H, Afinogenova Y, Zidan E, Kwah J, Russo A, Mamula M, Hsu FI, Catanzaro J, Racke M, Bucala R, Wilen C, Kang I. Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency. Journal Of Clinical Immunology 2022, 42: 1137-1150. PMID: 35713752, PMCID: PMC9203263, DOI: 10.1007/s10875-022-01296-4.
- “Near Cure” treatment of severe acute EAE in MIF-1-deficient female and male mice with a bifunctional MHCII-derived molecular constructVandenbark AA, Meza-Romero R, Wiedrick J, Gerstner G, Seifert H, Kent G, Piechycna M, Benedek G, Bucala R, Offner H. “Near Cure” treatment of severe acute EAE in MIF-1-deficient female and male mice with a bifunctional MHCII-derived molecular construct. Cellular Immunology 2022, 378: 104561. PMID: 35738135, PMCID: PMC9714992, DOI: 10.1016/j.cellimm.2022.104561.
- Bladder Oxidative Stress and HMGB1 Release Contribute to PAR4-Mediated Bladder Pain in MiceYe S, Ma F, Mahmood DFD, Meyer-Siegler KL, Leng L, Bucala R, Vera PL. Bladder Oxidative Stress and HMGB1 Release Contribute to PAR4-Mediated Bladder Pain in Mice. Frontiers In Systems Neuroscience 2022, 16: 882493. PMID: 35645739, PMCID: PMC9135998, DOI: 10.3389/fnsys.2022.882493.
- Arthritis & Rheumatology: “Mid‐Term” ReportSolomon DH, Bucala R, Kaplan MJ, Nigrovic PA. Arthritis & Rheumatology: “Mid‐Term” Report. Arthritis & Rheumatology 2022, 74: 1099-1101. PMID: 35358367, DOI: 10.1002/art.42131.
- Profibrotic Role for a Dysregulated D-Dopachrome Tautomerase-Cullin 3 Signaling Axis in Alveolar Type II Epithelial CellsKim S, Yang T, Peng X, Leng L, Bucala R, Lee P, Herzog E, Sauler M. Profibrotic Role for a Dysregulated D-Dopachrome Tautomerase-Cullin 3 Signaling Axis in Alveolar Type II Epithelial Cells. 2022, a2323-a2323. DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2323.
- The Role of CD74 in Bleomycin-Induced Pulmonary FibrosisYang T, Kim S, Leng L, Nouws J, Bucala R, Sauler M. The Role of CD74 in Bleomycin-Induced Pulmonary Fibrosis. 2022, a5334-a5334. DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5334.
- MP07-05 BLADDER OXIDATIVE STRESS AND ERK SIGNALING CONTRIBUTE TO BLADDER PAIN MEDIATED BY MACROPHAGE MIGRATION INHIBITORY FACTOR AND HIGH MOBILITY GROUP BOX 1Ye S, Ma F, Mahmood D, Meyer-Siegler K, Leng L, Bucala R, Vera P. MP07-05 BLADDER OXIDATIVE STRESS AND ERK SIGNALING CONTRIBUTE TO BLADDER PAIN MEDIATED BY MACROPHAGE MIGRATION INHIBITORY FACTOR AND HIGH MOBILITY GROUP BOX 1. Investigative Urology 2022, 207: e116. DOI: 10.1097/ju.0000000000002529.05.
- Managing COVID-19 going forward—the lessons from historyBucala R, Friedland G, Snowden F. Managing COVID-19 going forward—the lessons from history. QJM 2022, 115: hcac065. PMID: 35262710, PMCID: PMC9383561, DOI: 10.1093/qjmed/hcac065.
- Interleukin-17 Contributes to Chikungunya Virus-Induced DiseaseLiu X, Poo YS, Alves JC, Almeida RP, Mostafavi H, Tang PCH, Bucala R, Teixeira MM, Taylor A, Zaid A, Mahalingam S. Interleukin-17 Contributes to Chikungunya Virus-Induced Disease. MBio 2022, 13: e00289-22. PMID: 35254128, PMCID: PMC9040832, DOI: 10.1128/mbio.00289-22.
- Macrophage migration inhibitory factor regulates specific innate immune sensor responses in gingival epithelial cellsKantrong N, Chang AM, Bamashmous S, Hajjar AM, Bucala RJ, Darveau RP. Macrophage migration inhibitory factor regulates specific innate immune sensor responses in gingival epithelial cells. Journal Of Periodontology 2022, 93: 1940-1950. PMID: 35100435, DOI: 10.1002/jper.21-0598.
- Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitisAlrabadi LS, Dutton A, Rabiee A, Roberts SJ, Deng Y, Cusack L, Silveira MG, Ciarleglio M, Bucala R, Sinha R, Boyer JL, Assis DN. Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis. JHEP Reports 2022, 4: 100450. PMID: 35434588, PMCID: PMC9011026, DOI: 10.1016/j.jhepr.2022.100450.
- Targeting fibrocytes in autoimmunityBucala RJ. Targeting fibrocytes in autoimmunity. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2121739119. PMID: 35086933, PMCID: PMC8812540, DOI: 10.1073/pnas.2121739119.
- CD74 ablation rescues type 2 diabetes mellitus-induced cardiac remodeling and contractile dysfunction through pyroptosis-evoked regulation of ferroptosisChen L, Yin Z, Qin X, Zhu X, Chen X, Ding G, Sun D, Wu NN, Fei J, Bi Y, Zhang J, Bucala R, Ren J, Zheng Q. CD74 ablation rescues type 2 diabetes mellitus-induced cardiac remodeling and contractile dysfunction through pyroptosis-evoked regulation of ferroptosis. Pharmacological Research 2022, 176: 106086. PMID: 35033649, DOI: 10.1016/j.phrs.2022.106086.
- Canonical (CD74/CD44) and Non-Canonical (CXCR2, 4 and 7) MIF Receptors Are Differentially Expressed in Rheumatoid Arthritis Patients Evaluated by DAS28-ESRSánchez-Zuno GA, Bucala R, Hernández-Bello J, Román-Fernández IV, García-Chagollán M, Nicoletti F, Matuz-Flores MG, García-Arellano S, Esparza-Michel JA, Cerpa-Cruz S, Pérez-Guerrero EE, Muñoz-Valle JF. Canonical (CD74/CD44) and Non-Canonical (CXCR2, 4 and 7) MIF Receptors Are Differentially Expressed in Rheumatoid Arthritis Patients Evaluated by DAS28-ESR. Journal Of Clinical Medicine 2021, 11: 120. PMID: 35011861, PMCID: PMC8745239, DOI: 10.3390/jcm11010120.
- Global Rheumatology Research: Frontiers, Challenges, and OpportunitiesBilsborrow JB, Peláez‐Ballestas I, Pons‐Estel B, Scott C, Tian X, Alarcon GS, Bucala R, Lewandowski LB, Hsieh E. Global Rheumatology Research: Frontiers, Challenges, and Opportunities. Arthritis & Rheumatology 2021, 74: 1-4. PMID: 34535973, PMCID: PMC8712358, DOI: 10.1002/art.41980.
- MIF but not MIF-2 recruits inflammatory macrophages in an experimental polymicrobial sepsis modelTilstam PV, Schulte W, Holowka T, Kim BS, Nouws J, Sauler M, Piecychna M, Pantouris G, Lolis E, Leng L, Bernhagen J, Fingerle-Rowson G, Bucala R. MIF but not MIF-2 recruits inflammatory macrophages in an experimental polymicrobial sepsis model. Journal Of Clinical Investigation 2021, 131: e127171. PMID: 34850744, PMCID: PMC8631602, DOI: 10.1172/jci127171.
- Macrophage migration inhibitory factor exerts pro-proliferative and anti-apoptotic effects via CD74 in murine hepatocellular carcinomaWirtz T, Saal A, Bergmann I, Fischer P, Heinrichs D, Brandt E, Koenen M, Djudjaj S, Schneider K, Boor P, Bucala R, Weiskirchen R, Bernhagen J, Trautwein C, Berres M. Macrophage migration inhibitory factor exerts pro-proliferative and anti-apoptotic effects via CD74 in murine hepatocellular carcinoma. Zeitschrift Für Gastroenterologie 2021, 59: e206-e207. DOI: 10.1055/s-0041-1733611.
- ICBP90 Regulates MIF Expression, Glucocorticoid Sensitivity, and Apoptosis at the MIF Immune Susceptibility LocusYao J, Leng L, Fu W, Li J, Bronner C, Bucala R. ICBP90 Regulates MIF Expression, Glucocorticoid Sensitivity, and Apoptosis at the MIF Immune Susceptibility Locus. Arthritis & Rheumatology 2021, 73: 1931-1942. PMID: 33844457, DOI: 10.1002/art.41753.
- MP08-05 BLADDER MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) RECEPTORS MEDIATE PAINYe S, Ma F, Mahmood D, Meyer-Siegler K, Menard R, Hunt D, Leng L, Bucala R, Vera P. MP08-05 BLADDER MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) RECEPTORS MEDIATE PAIN. Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000001981.05.
- Macrophage migration inhibitory factor exerts pro‐proliferative and anti‐apoptotic effects via CD74 in murine hepatocellular carcinomaWirtz TH, Saal A, Bergmann I, Fischer P, Heinrichs D, Brandt EF, Koenen MT, Djudjaj S, Schneider KM, Boor P, Bucala R, Weiskirchen R, Bernhagen J, Trautwein C, Berres M. Macrophage migration inhibitory factor exerts pro‐proliferative and anti‐apoptotic effects via CD74 in murine hepatocellular carcinoma. British Journal Of Pharmacology 2021, 178: 4452-4467. PMID: 34250589, DOI: 10.1111/bph.15622.
- Intravesical CD74 and CXCR4, macrophage migration inhibitory factor (MIF) receptors, mediate bladder painYe S, Ma F, Mahmood DFD, Meyer-Siegler KL, Menard RE, Hunt DE, Leng L, Bucala R, Vera PL. Intravesical CD74 and CXCR4, macrophage migration inhibitory factor (MIF) receptors, mediate bladder pain. PLOS ONE 2021, 16: e0255975. PMID: 34424927, PMCID: PMC8382170, DOI: 10.1371/journal.pone.0255975.
- 197-LB: The Regulation of HSL by Macrophage Migration Inhibitory Factor (MIF) Contributes to Adipocyte Hypertrophy and Development of ObesityCHEN L, HUANG Y, LI L, ZABIHI H, QI Y, LENG L, SUN G, BUCALA R, QI D. 197-LB: The Regulation of HSL by Macrophage Migration Inhibitory Factor (MIF) Contributes to Adipocyte Hypertrophy and Development of Obesity. Diabetes 2021, 70 DOI: 10.2337/db21-197-lb.
- ResponsePrice CC, Altice FL, Azar MM, McManus D, Gleeson SE, Britto CJ, Azmy V, Kaman K, Davis M, Chupp G, Bucala R, Kaminski N, Topal JE, Dela Cruz C, Malinis M. Response. CHEST Journal 2021, 159: 2116-2117. PMID: 33965143, PMCID: PMC8097398, DOI: 10.1016/j.chest.2020.12.032.
- Role of MIF in coordinated expression of hepatic chemokines in patients with alcohol-associated hepatitisPoulsen KL, Fan X, Kibler CD, Huang E, Wu X, McMullen MR, Leng L, Bucala R, Ventura-Cots M, Argemi J, Bataller R, Nagy LE. Role of MIF in coordinated expression of hepatic chemokines in patients with alcohol-associated hepatitis. JCI Insight 2021, 6: e141420. PMID: 33945507, PMCID: PMC8262327, DOI: 10.1172/jci.insight.141420.
- 17‐a‐estradiol late in life extends lifespan in aging UM‐HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sexHarrison DE, Strong R, Reifsnyder P, Kumar N, Fernandez E, Flurkey K, Javors MA, Lopez‐Cruzan M, Macchiarini F, Nelson JF, Markewych A, Bitto A, Sindler AL, Cortopassi G, Kavanagh K, Leng L, Bucala R, Rosenthal N, Salmon A, Stearns TM, Bogue M, Miller RA. 17‐a‐estradiol late in life extends lifespan in aging UM‐HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex. Aging Cell 2021, 20: e13328. PMID: 33788371, PMCID: PMC8135004, DOI: 10.1111/acel.13328.
- CD74 is a regulator of hematopoietic stem cell maintenanceBecker-Herman S, Rozenberg M, Hillel-Karniel C, Gil-Yarom N, Kramer M, Barak A, Sever L, David K, Radomir L, Lewinsky H, Levi M, Friedlander G, Bucala R, Peled A, Shachar I. CD74 is a regulator of hematopoietic stem cell maintenance. PLOS Biology 2021, 19: e3001121. PMID: 33661886, PMCID: PMC7963458, DOI: 10.1371/journal.pbio.3001121.
- Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancerKlemke L, De Oliveira T, Witt D, Winkler N, Bohnenberger H, Bucala R, Conradi LC, Schulz-Heddergott R. Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer. Cell Death & Disease 2021, 12: 155. PMID: 33542244, PMCID: PMC7862487, DOI: 10.1038/s41419-021-03426-z.
- Unexpected Pro-Fibrotic Effect of MIF in Non-Alcoholic Steatohepatitis Is Linked to a Shift in NKT Cell PopulationsHeinrichs D, Brandt EF, Fischer P, Köhncke J, Wirtz TH, Guldiken N, Djudjaj S, Boor P, Kroy D, Weiskirchen R, Bucala R, Wasmuth HE, Strnad P, Trautwein C, Bernhagen J, Berres ML. Unexpected Pro-Fibrotic Effect of MIF in Non-Alcoholic Steatohepatitis Is Linked to a Shift in NKT Cell Populations. Cells 2021, 10: 252. PMID: 33525493, PMCID: PMC7918903, DOI: 10.3390/cells10020252.
- Chapter 11 Interferons and cytokines in SLE pathogenesis and therapyKoumpouras F, Bucala R. Chapter 11 Interferons and cytokines in SLE pathogenesis and therapy. 2021, 169-180. DOI: 10.1016/b978-0-12-820583-9.00015-4.
- Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosisWirtz TH, Reuken PA, Jansen C, Fischer P, Bergmann I, Backhaus C, Emontzpohl C, Reißing J, Brandt EF, Koenen MT, Schneider KM, Schierwagen R, Brol MJ, Chang J, Zimmermann HW, Köse-Vogel N, Eggermann T, Kurth I, Stoppe C, Bucala R, Bernhagen J, Praktiknjo M, Stallmach A, Trautwein C, Trebicka J, Bruns T, Berres ML. Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosis. JHEP Reports 2020, 3: 100221. PMID: 33659891, PMCID: PMC7890204, DOI: 10.1016/j.jhepr.2020.100221.
- Corrigendum to “Haploinsufficiency of multiple del(5q) genes induce B cell abnormalities in mice” [Leuk. Res. 96C (2020) 106428]Liu T, Ahmed T, Krysiak K, Shirai CL, Shao J, Nunley R, Bucala R, McKenzie A, Ndonwi M, Walter MJ. Corrigendum to “Haploinsufficiency of multiple del(5q) genes induce B cell abnormalities in mice” [Leuk. Res. 96C (2020) 106428]. Leukemia Research 2020, 100: 106478. PMID: 33288274, DOI: 10.1016/j.leukres.2020.106478.
- Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targetingKontos C, El Bounkari O, Krammer C, Sinitski D, Hille K, Zan C, Yan G, Wang S, Gao Y, Brandhofer M, Megens RTA, Hoffmann A, Pauli J, Asare Y, Gerra S, Bourilhon P, Leng L, Eckstein HH, Kempf WE, Pelisek J, Gokce O, Maegdefessel L, Bucala R, Dichgans M, Weber C, Kapurniotu A, Bernhagen J. Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting. Nature Communications 2020, 11: 5981. PMID: 33239628, PMCID: PMC7689490, DOI: 10.1038/s41467-020-19764-z.
- Abstract 14834: Protective Role of Cardiomyocyte-derived Ddt in Ischemic CardiomyopathyMa Y, Hu X, Pfau D, Wu X, Rao V, Testani J, Margulies K, Bucala R, Young L. Abstract 14834: Protective Role of Cardiomyocyte-derived Ddt in Ischemic Cardiomyopathy. Circulation 2020, 142 DOI: 10.1161/circ.142.suppl_3.14834.
- MIF-CD74 Signaling Protects Against Endothelial Senescence in Chronic Obstructive Pulmonary DiseaseKim S, Wan F, Zhang X, Zhang Y, Ifedigbo E, Leng L, Bucala R, Lee P, Sauler M. MIF-CD74 Signaling Protects Against Endothelial Senescence in Chronic Obstructive Pulmonary Disease. 2020, a4374-a4374. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4374.
- MIF‐CD74 Signaling Protects against Endothelial Senescence in Chronic Obstructive Pulmonary DiseaseKim S, Wan F, Zhang X, Zhang Y, Ifedigbo E, Leng L, Bucala R, Sauler M, Lee P. MIF‐CD74 Signaling Protects against Endothelial Senescence in Chronic Obstructive Pulmonary Disease. The FASEB Journal 2020, 34: 1-1. DOI: 10.1096/fasebj.2020.34.s1.04905.
- MP28-13 ACTIVATION OF INTRAVESICAL MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) RECEPTORS MEDIATES BLADDER PAINYe S, Ma F, Meyer-Siegler K, Leng L, Bucala R, Vera* P. MP28-13 ACTIVATION OF INTRAVESICAL MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) RECEPTORS MEDIATES BLADDER PAIN. Investigative Urology 2020, 203 DOI: 10.1097/ju.0000000000000867.013.
- GENE-26. HOST GENETIC VARIATIONS IN MACROPHAGE MIGRATION INHIBITOR FACTOR CONFER WORSE PROGNOSIS IN GLIOBLASTOMAOtvos B, Grabowski M, Alban T, Golubovsky J, Neumann C, Rabjlenovic A, Bayik D, Lauko A, Bucala R, Vogelbaum M, Lathia J. GENE-26. HOST GENETIC VARIATIONS IN MACROPHAGE MIGRATION INHIBITOR FACTOR CONFER WORSE PROGNOSIS IN GLIOBLASTOMA. Neuro-Oncology 2019, 21: vi103-vi103. PMCID: PMC6847914, DOI: 10.1093/neuonc/noz175.428.
- IMMU-28. TARGETING IMMUNOSUPPRESSIVE MYELOID DERIVED SUPPRESSOR CELLS VIA MIF/CD74 SIGNALING AXIS TO ATTENUATE GBM GROWTHAlban T, Bayik D, Otvos B, Grabowski M, Ahluwalia M, Bucala R, Vogelbaum M, Lathia J. IMMU-28. TARGETING IMMUNOSUPPRESSIVE MYELOID DERIVED SUPPRESSOR CELLS VIA MIF/CD74 SIGNALING AXIS TO ATTENUATE GBM GROWTH. Neuro-Oncology 2019, 21: vi125-vi125. PMCID: PMC6847354, DOI: 10.1093/neuonc/noz175.521.
- Immunoepidemiology of Mycobacterium tuberculosisOdio C, Bucala R. Immunoepidemiology of Mycobacterium tuberculosis. 2019, 151-163. DOI: 10.1007/978-3-030-25553-4_9.
- 2598. Macrophage Migration Inhibitory Factor May Contribute to Disseminated Coccidioidomycosis SusceptibilityOdio C, Leng L, Siu E, Piecychna M, Galgiani J, Holland S, Bucala R. 2598. Macrophage Migration Inhibitory Factor May Contribute to Disseminated Coccidioidomycosis Susceptibility. Open Forum Infectious Diseases 2019, 6: s903-s903. PMCID: PMC6810323, DOI: 10.1093/ofid/ofz360.2276.
- 830 Can CD74 Predict Treatment Response to Anti-TNF Agents in Inflammatory Bowel Disease?Farr L, Bucala R, Moonah S. 830 Can CD74 Predict Treatment Response to Anti-TNF Agents in Inflammatory Bowel Disease? The American Journal Of Gastroenterology 2019, 114: s480-s480. DOI: 10.14309/01.ajg.0000592856.82828.b1.
- Abstract 875: Cardiomyocyte Derived DDT Protects Against Myocardial Infarction Induced Heart FailureMa Y, Hu X, Wu X, Pfau D, Leng L, Bedi K, Margulies K, Bucala R, Young L. Abstract 875: Cardiomyocyte Derived DDT Protects Against Myocardial Infarction Induced Heart Failure. Circulation Research 2019, 125 DOI: 10.1161/res.125.suppl_1.875.
- Protective Role of D-Dopachrome Tautomerase (MIF2) in Chronic Obstructive Pulmonary DiseaseArdito T, Nouws J, Kim S, Zhang Y, Bucala R, Lee P, Sauler M. Protective Role of D-Dopachrome Tautomerase (MIF2) in Chronic Obstructive Pulmonary Disease. 2019, a5374-a5374. DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5374.
- Selective Recruitment of Lethal Pro-inflammatory Macrophages in Sepsis by MIF but not D-DT (MIF-2)Tilstam P, Schulte W, Holowka T, Kim B, Piecychna M, Pantouris G, Lolis E, Leng L, Bernhagen J, Bucala R. Selective Recruitment of Lethal Pro-inflammatory Macrophages in Sepsis by MIF but not D-DT (MIF-2). The Journal Of Immunology 2019, 202: 51.9-51.9. DOI: 10.4049/jimmunol.202.supp.51.9.
- MIF and MIF2 have distinct but synergistic roles in CIA pathogenesisDoherty E, Tilstam P, Bucala R. MIF and MIF2 have distinct but synergistic roles in CIA pathogenesis. The Journal Of Immunology 2019, 202: 180.13-180.13. DOI: 10.4049/jimmunol.202.supp.180.13.
- Chapter 83 Adaptive Immunity and Critical IllnessSchulte W, Maerz L, Moeckel G, Bucala R. Chapter 83 Adaptive Immunity and Critical Illness. 2019, 483-487. DOI: 10.1016/b978-0-323-44942-7.00083-2.
- A Fresh New Look, and a Fresh New JournalHannan MT, Bucala R. A Fresh New Look, and a Fresh New Journal. Arthritis Care & Research 2018, 71: 1-1. PMID: 30199145, DOI: 10.1002/acr.23751.
- A functional macrophage migration inhibitory factor promoter polymorphism is associated with reduced diffusing capacityZhang C, Ramsey C, Berical A, Yu L, Leng L, McGinnis K, Song Y, Michael H, McCormack M, Allore H, Morris A, Crothers K, Bucala R, Lee P, Sauler M. A functional macrophage migration inhibitory factor promoter polymorphism is associated with reduced diffusing capacity. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2018, 316: l400-l405. PMID: 30520689, PMCID: PMC6397351, DOI: 10.1152/ajplung.00439.2018.
- Selective Recruitment of a Lethal Macrophage Subset in Sepsis by Macrophage Migration Inhibitory Factor But Not Its Homologue MIF2Schulte W, Tilstam P, Holowka T, Piecychna M, Leng L, Bernhagen J, Bucala R. Selective Recruitment of a Lethal Macrophage Subset in Sepsis by Macrophage Migration Inhibitory Factor But Not Its Homologue MIF2. Journal Of The American College Of Surgeons 2018, 227: s82. DOI: 10.1016/j.jamcollsurg.2018.07.118.
- 4148Activation of canonical proinflammatory pathways in smooth muscle cells exerts paradoxical atheroprotective effectsStark K, Pekayvaz K, Hoseinpour P, Coletti R, Gold C, Ishikawa-Ankerhold H, Lorenz M, Fingerle-Rowson G, Bucala R, Schulz C, Massberg S. 4148Activation of canonical proinflammatory pathways in smooth muscle cells exerts paradoxical atheroprotective effects. European Heart Journal 2018, 39 DOI: 10.1093/eurheartj/ehy563.4148.
- Nanosecond Dynamics Regulate the MIF‐Induced Activity of CD74Pantouris G, Ho J, Shah D, Syed M, Leng L, Bhandari V, Bucala R, Batista V, Loria J, Lolis E. Nanosecond Dynamics Regulate the MIF‐Induced Activity of CD74. Angewandte Chemie 2018, 130: 7234-7237. DOI: 10.1002/ange.201803191.
- PD55-03 PAR4 ACTIVATION AS A PERSISTENT MODEL OF BLADDER PAIN: ROLE OF MIF AND HMGB1Ma F, Hunt D, Leng L, Bucala R, Meyer-Siegler K, Vera P. PD55-03 PAR4 ACTIVATION AS A PERSISTENT MODEL OF BLADDER PAIN: ROLE OF MIF AND HMGB1. Investigative Urology 2018, 199: e1056-e1057. DOI: 10.1016/j.juro.2018.02.2623.
- FRI-068 Novel pro-fibrotic properties of macrophage migration inhibitory factor in non-alcoholic steatohepatitis is associated with a shift in natural killer T cell populationsHeinrichs D, Brandt E, Fischer P, Koehncke J, Wirtz T, Djudjaj S, Boor P, Bucala R, Kroy D, Schumacher F, Wasmuth H, Trautwein C, Bernhagen J, Berres M. FRI-068 Novel pro-fibrotic properties of macrophage migration inhibitory factor in non-alcoholic steatohepatitis is associated with a shift in natural killer T cell populations. Journal Of Hepatology 2018, 68: s392. DOI: 10.1016/s0168-8278(18)31017-1.
- PS-083 Protection from Gao-Binge induced liver injury in Mif–/– Mice is associated with decreased ER stressPoulsen K, Mcmullen M, Sheehan M, Leng L, Bucala R, Nagy L. PS-083 Protection from Gao-Binge induced liver injury in Mif–/– Mice is associated with decreased ER stress. Journal Of Hepatology 2018, 68: s47-s48. DOI: 10.1016/s0168-8278(18)30313-1.
- MalariaMcDevitt M, Bucala R. Malaria. 2017, 108-112. DOI: 10.1017/9781108586900.016.
- Parasite MIF OrthologsHolowka T, Bucala R. Parasite MIF Orthologs. 2017, 221-239. DOI: 10.1007/978-3-319-52354-5_14.
- Adoptive transfer of a novel MIF receptor (CD74+) expressing memory T cell subpopulation is sufficient to transfer inflammatory arthritisDoherty E, Piecychna M, Leng L, Bucala R. Adoptive transfer of a novel MIF receptor (CD74+) expressing memory T cell subpopulation is sufficient to transfer inflammatory arthritis. The Journal Of Immunology 2017, 198: 156.3-156.3. DOI: 10.4049/jimmunol.198.supp.156.3.
- Macrophage Migration Inhibitory Factor Serves As an Upstream Regulator of NLRP3 Expression and Subsequent IL-1beta Production in Human Monocytes in Response to Lupus U1-snRNP Immune ComplexShin M, Kang Y, Leng L, Bucala R, Kang I. Macrophage Migration Inhibitory Factor Serves As an Upstream Regulator of NLRP3 Expression and Subsequent IL-1beta Production in Human Monocytes in Response to Lupus U1-snRNP Immune Complex. The Journal Of Immunology 2017, 198: 210.3-210.3. DOI: 10.4049/jimmunol.198.supp.210.3.
- FRI-393 Macrophage migration inhibitory factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver diseaseRoberts S, Leng L, Soroka C, Boyer J, Bucala R, Assis D. FRI-393 Macrophage migration inhibitory factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver disease. Journal Of Hepatology 2017, 66: s363-s364. DOI: 10.1016/s0168-8278(17)31067-x.
- 258 Macrophage Migration Inhibitory Factor (MIF) promotes TH17 cell-driven psoriasiform dermatitisBezdek S, Mousavi S, Hadenah A, Zillikens D, Bucala R, Sadik C. 258 Macrophage Migration Inhibitory Factor (MIF) promotes TH17 cell-driven psoriasiform dermatitis. Journal Of Investigative Dermatology 2016, 136: s205. DOI: 10.1016/j.jid.2016.06.278.
- CD74-dysregulation of placental macrophage-trophoblastic interactions in preeclampsiaPrzybyl L, Haase N, Golic M, Rugor J, Solano M, Arck P, Gauster M, Huppertz B, Stoppe C, Bernhagen J, Bucala R, Johnsen G, Peetz D, Luft F, Staff A, Müller D, Dechend R, Herse F. CD74-dysregulation of placental macrophage-trophoblastic interactions in preeclampsia. Journal Of Reproductive Immunology 2016, 115: 41-42. DOI: 10.1016/j.jri.2016.04.126.
- Abstract 16602: The Clinical Significance of Mif, Mif-2 and Mif Genotype in Patients Exhibited to Myocardial Ischemia/reperfusion InjuryStoppe C, Goetzenich A, Kraemer S, Emontzpohl C, Soppert J, Bucala R, Weber C, Bernhagen J. Abstract 16602: The Clinical Significance of Mif, Mif-2 and Mif Genotype in Patients Exhibited to Myocardial Ischemia/reperfusion Injury. Circulation 2015, 132 DOI: 10.1161/circ.132.suppl_3.16602.
- Abstract 042: Cd74-dysregulation of Macrophage-trophoblastic Interactions in the Preeclamptic PlacentaPrzybyl L, Haase N, Golic M, Rugor J, Solano M, Arck P, Gauster M, Huppertz B, Bernhagen J, Bucala R, Luft F, Staff A, Mueller D, Dechend R, Herse F. Abstract 042: Cd74-dysregulation of Macrophage-trophoblastic Interactions in the Preeclamptic Placenta. Hypertension 2015, 66 DOI: 10.1161/hyp.66.suppl_1.042.
- SP0184 Selecting the Best Journal for Communicating Research FindingsBucala R. SP0184 Selecting the Best Journal for Communicating Research Findings. Annals Of The Rheumatic Diseases 2015, 74: 45. DOI: 10.1136/annrheumdis-2015-eular.6820.
- 1677Macrophage migration inhibitory factor (MIF) promotes clearance of pneumococcal colonizationDas R, Larose M, Hergott C, Leng L, Bucala R, Weiser J. 1677Macrophage migration inhibitory factor (MIF) promotes clearance of pneumococcal colonization. Open Forum Infectious Diseases 2014, 1: s448-s448. PMCID: PMC5782292, DOI: 10.1093/ofid/ofu052.1223.
- Erratum to ‘Differential roles of cardiac and leukocyte derived macrophage migration inhibitory factor in inflammatory responses and cardiac remodelling post myocardial infarction’ [J Mol Cell Cardiol 69 (2014) 32–42]White D, Su Y, Kanellakis P, Kiriazis H, Morand E, Bucala R, Dart A, Du X, Gao X. Erratum to ‘Differential roles of cardiac and leukocyte derived macrophage migration inhibitory factor in inflammatory responses and cardiac remodelling post myocardial infarction’ [J Mol Cell Cardiol 69 (2014) 32–42]. Journal Of Molecular And Cellular Cardiology 2014, 75: 198. DOI: 10.1016/j.yjmcc.2014.08.005.
- Metallothioneins in Fibrosis: Implications for Radiation-Induced FibrosisBlakaj A, Chi X, Mourad W, Herzog E, Leng L, Bucala R. Metallothioneins in Fibrosis: Implications for Radiation-Induced Fibrosis. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s684-s685. DOI: 10.1016/j.ijrobp.2014.05.2011.
- Deletion of macrophage migration inhibitory factor reduces severity of osteoarthritis in miceGreene M, Roland A, Pritzker L, Carlson C, Bucala R, Miller R, Loeser R. Deletion of macrophage migration inhibitory factor reduces severity of osteoarthritis in mice. Osteoarthritis And Cartilage 2014, 22: s58-s59. DOI: 10.1016/j.joca.2014.02.122.
- The Scientific and Medical Challenge of MalariaSun T, Bucala R. The Scientific and Medical Challenge of Malaria. 2014, 189-215. DOI: 10.1142/9789814405584_0008.
- In Memoriam: Stephen E. Malawista, MD, 1934–2013Montgomery R, Bucala R, Bockenstedt L. In Memoriam: Stephen E. Malawista, MD, 1934–2013. Arthritis & Rheumatology 2013, 66: 1-1. DOI: 10.1002/art.38233.
- CD84 is a survival receptor for chronic lymphocytic leukemia cells (P2044)Marom A, Binsky-Ehrenreich I, Sobotta M, Shvidel L, Berrebi A, Hazan-Halevy I, Kay S, Aloshin A, Sagi I, Goldenberg D, Leng L, Bucala R, Herishanu Y, Haran M, Shachar I. CD84 is a survival receptor for chronic lymphocytic leukemia cells (P2044). The Journal Of Immunology 2013, 190: 132.12-132.12. DOI: 10.4049/jimmunol.190.supp.132.12.
- Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects (P5221)Benedek G, Meza-Romero R, Andrew S, Leng L, Burrows G, Bourdette D, Offner H, Bucala R, Vandenbark A. Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects (P5221). The Journal Of Immunology 2013, 190: 67.4-67.4. DOI: 10.4049/jimmunol.190.supp.67.4.
- Role of MIF gene polymorphisms in systemic lupus erythematosus and prospects for therapeutic interventionBucala R. Role of MIF gene polymorphisms in systemic lupus erythematosus and prospects for therapeutic intervention. Arthritis Research & Therapy 2012, 14: a33. PMCID: PMC3467510, DOI: 10.1186/ar3967.
- 40. Antidepressant effects of macrophage migration inhibitory factor using a knockout mouse approachBay-Richter C, Janelidze S, Bucala R, Deierborg T, Brundin L. 40. Antidepressant effects of macrophage migration inhibitory factor using a knockout mouse approach. Brain Behavior And Immunity 2012, 26: s11-s12. DOI: 10.1016/j.bbi.2012.07.064.
- MIF, MIF Alleles, and the Regulation of the Host ResponseBucala R. MIF, MIF Alleles, and the Regulation of the Host Response. 2012, 3-22. DOI: 10.1142/9789814335362_0001.
- 1240 A FUNCTIONAL ROLE OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) FOR FATTY LIVER DISEASE AND OBESITY IN MICEHeinrichs D, Knauel M, Nellen A, Trautwein C, Bucala R, Bernhagen J, Wasmuth H. 1240 A FUNCTIONAL ROLE OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) FOR FATTY LIVER DISEASE AND OBESITY IN MICE. Journal Of Hepatology 2012, 56: s491. DOI: 10.1016/s0168-8278(12)61252-5.
- A functional role of Macrophage Migration Inhibitory Factor (MIF) for liver steatosis in mice by activation of AMP kinaseHeinrichs D, Knauel M, Nellen A, Schmitz P, Trautwein C, Bucala R, Bernhagen J, Wasmuth H. A functional role of Macrophage Migration Inhibitory Factor (MIF) for liver steatosis in mice by activation of AMP kinase. Zeitschrift Für Gastroenterologie 2012, 50 DOI: 10.1055/s-0031-1295805.
- Fibrocytes in the Etiopathogenesis of Nephrogenic Systemic FibrosisBucala R. Fibrocytes in the Etiopathogenesis of Nephrogenic Systemic Fibrosis. 2011, 185-195. DOI: 10.1142/9789814343725_0011.
- 1.23 The Cytokine Midkine and its Receptor Tyrosine Phosphatase Zeta Regulate B Cell Survival in Health and Disease in a Pathway Induced by CD74Cohen S, Shoshana O, Zelman-Toister E, Maharshak N, Ehrenreich I, Gordin M, Shvidel L, Haran M, Leng L, Bucala R, Harroch S, Shachar I. 1.23 The Cytokine Midkine and its Receptor Tyrosine Phosphatase Zeta Regulate B Cell Survival in Health and Disease in a Pathway Induced by CD74. Clinical Lymphoma Myeloma & Leukemia 2011, 11: s156. DOI: 10.1016/j.clml.2011.09.024.
- P60. S-Nitros(yl)ation regulates the cardioprotective properties of macrophage migration inhibitory factorLuedike P, Hendgen-Cotta U, Totzeck M, Reeh M, Sobierajski J, Dewor M, Hongqi L, Krisp C, Wolters D, Bucala R, Kelm M, Bernhagen J, Rassaf T. P60. S-Nitros(yl)ation regulates the cardioprotective properties of macrophage migration inhibitory factor. Nitric Oxide 2011, 24: s37-s38. DOI: 10.1016/j.niox.2011.03.291.
- 1038 MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) ACTS AS AN ANTI-FIBROTIC CYTOKINE IN EXPERIMENTAL LIVER FIBROSIS VIA CD74 AND AMPKHeinrichs P, Jung M, Offermanns C, Berres M, Nellen A, Schmitz P, Leng L, Bucala R, Trautwein C, Weber C, Bernhagen J, Wasmuth H. 1038 MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) ACTS AS AN ANTI-FIBROTIC CYTOKINE IN EXPERIMENTAL LIVER FIBROSIS VIA CD74 AND AMPK. Journal Of Hepatology 2011, 54: s413. DOI: 10.1016/s0168-8278(11)61040-4.
- MIF exerts anti-fibrotic effects in experimental liver fibrosis via CD74Heinrichs D, Jung M, Berres M, Nellen A, Schmitz P, Bucala R, Trautwein C, Weber C, Bernhagen J, Wasmuth H. MIF exerts anti-fibrotic effects in experimental liver fibrosis via CD74. Zeitschrift Für Gastroenterologie 2011, 49 DOI: 10.1055/s-0030-1269517.
- Is Nephrogenic Systemic Fibrosis a Disease of Fibrocytes?Bucala R. Is Nephrogenic Systemic Fibrosis a Disease of Fibrocytes? Current Rheumatology Reviews 2010, 6: 171-175. DOI: 10.2174/157339710791792667.
- Editorial [Hot Topic: Nephrogenic Systemic Fibrosis (Guest Editor: Richard Bucala)]Bucala R. Editorial [Hot Topic: Nephrogenic Systemic Fibrosis (Guest Editor: Richard Bucala)]. Current Rheumatology Reviews 2010, 6: 162-162. DOI: 10.2174/157339710791792711.
- ChemInform Abstract: Model Studies of the Maillard Reaction of Arg‐Lys with D‐GlucoseAl‐Abed Y, Callaway D, Kapurniotu A, Holak T, Voelter W, Bucala R. ChemInform Abstract: Model Studies of the Maillard Reaction of Arg‐Lys with D‐Glucose. ChemInform 2010, 30: no-no. DOI: 10.1002/chin.199918292.
- ChemInform Abstract: A Polyhydroxylated Cyclopentene: A Useful Synthon Toward the Synthesis of Carbocyclic D‐Fructofuranoside.Seepersaud M, Bucala R, Al‐Abed Y. ChemInform Abstract: A Polyhydroxylated Cyclopentene: A Useful Synthon Toward the Synthesis of Carbocyclic D‐Fructofuranoside. ChemInform 2010, 30: no-no. DOI: 10.1002/chin.199932226.
- ChemInform Abstract: Inhibition of Macrophage Migration Inhibitory Factor (MIF) Tautomerase Activity by Dopachrome AnaloguesZhang X, Bucala R. ChemInform Abstract: Inhibition of Macrophage Migration Inhibitory Factor (MIF) Tautomerase Activity by Dopachrome Analogues. ChemInform 2010, 31: no-no. DOI: 10.1002/chin.200008138.
- P81 MIF-DEFICIENCY REDUCES CHRONIC INFLAMMATION IN ADIPOSE TISSUE AND IMPAIRS INSULIN RESISTANCE AND ASSOCIATED ATHEROSCLEROSIS IN A MODEL OF COMBINED DISEASEKleemann R, Verschuren L, Wielinga P, Voshol P, van Erk M, Fingerle-Rowson G, van Dijk K, Ouwens M, Bernhagen J, Bucala R, Kooistra T. P81 MIF-DEFICIENCY REDUCES CHRONIC INFLAMMATION IN ADIPOSE TISSUE AND IMPAIRS INSULIN RESISTANCE AND ASSOCIATED ATHEROSCLEROSIS IN A MODEL OF COMBINED DISEASE. Atherosclerosis Plus 2010, 11: 33. DOI: 10.1016/s1567-5688(10)70148-3.
- AV411 (Ibudilast) and AV1013 are non-competitive inhibitors of macrophage migration inhibitory factor: a novel induced-fit allosteric inhibition mechanism (133.11)Cho Y, Crichlow G, Vermeire J, Leng L, Du X, Hodsdon M, Bucala R, Cappello M, Gross M, Gaeta F, Johnson K, Lolis E. AV411 (Ibudilast) and AV1013 are non-competitive inhibitors of macrophage migration inhibitory factor: a novel induced-fit allosteric inhibition mechanism (133.11). The Journal Of Immunology 2010, 184: 133.11-133.11. DOI: 10.4049/jimmunol.184.supp.133.11.
- Differentiation, activation and function of CD11b+Ly6C+ TNF/iNOS-producing dendritic cells during parasitic infectionBosschaerts T, Guilliams M, Stijlemans B, Morias Y, Engel D, Tacke F, Richard B, VandenDriessche T, Chuah M, De Baetselier P, Beschin A. Differentiation, activation and function of CD11b+Ly6C+ TNF/iNOS-producing dendritic cells during parasitic infection. Cytokine 2009, 48: 135. DOI: 10.1016/j.cyto.2009.07.571.
- MRI in the era of nephrogenic systemic fibrosis: Review, controversies and suggestions for risk reductionKuo P, Abu-Alfa A, Bucala R, Griffith J, Carlson K, Girardi M, Weinreb J, Cowper S. MRI in the era of nephrogenic systemic fibrosis: Review, controversies and suggestions for risk reduction. Applied Radiology 2009, 22-33. DOI: 10.37549/ar1683.
- MACROPHAGE MIGRATION INHIBITORY FACTOR ANTI-THROMBIN III COMPLEXES ARE DECREASED IN BLADDER CANCER PATIENT SERUM: COMPLEX FORMATION AS A POSSIBLE MECHANISM OF MIF INACTIVATIONMeyer-Siegler K, Cox J, Leng L, Bucala R, Vera P. MACROPHAGE MIGRATION INHIBITORY FACTOR ANTI-THROMBIN III COMPLEXES ARE DECREASED IN BLADDER CANCER PATIENT SERUM: COMPLEX FORMATION AS A POSSIBLE MECHANISM OF MIF INACTIVATION. Investigative Urology 2009, 181: 304. DOI: 10.1016/s0022-5347(09)60867-3.
- Macrophage migration inhibitory factor and multiple organ dysfunction syndromeYende S, Angus D, Bucala R. Macrophage migration inhibitory factor and multiple organ dysfunction syndrome. Journal Of Organ Dysfunction 2009, 5: 10-16. DOI: 10.1080/17471060802443653.
- CHAPTER 151 The Macrophage in Innate and Adaptive ImmunityDoernberg S, Bucala R. CHAPTER 151 The Macrophage in Innate and Adaptive Immunity. 2009, 784-788. DOI: 10.1016/b978-1-4160-4252-5.50158-1.
- 350: Macrophage Migration Inhibitory Factor as a New Target in Graft-Versus-Host Disease after Allogeneic Stem Cell TransplantationChang Y, Miklos S, Mueller G, Holler E, Lindner P, Leng L, Schubert T, Bucala R, Hildebrandt G. 350: Macrophage Migration Inhibitory Factor as a New Target in Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation. Transplantation And Cellular Therapy 2008, 14: 128. DOI: 10.1016/j.bbmt.2007.12.360.
- Neutralization of Macrophage Migration Inhibitory Factor (MIF) Reduces GVHD but Preserves GVL.Miklos S, Mueller G, Lindner P, Chang Y, Holler E, Bucala R, Hildebrandt G. Neutralization of Macrophage Migration Inhibitory Factor (MIF) Reduces GVHD but Preserves GVL. Blood 2007, 110: 3234-3234. DOI: 10.1182/blood.v110.11.3234.3234.
- Culture and Analysis of Circulating FibrocytesQuan T, Bucala R. Culture and Analysis of Circulating Fibrocytes. 2007, 135: 423-434. DOI: 10.1385/1-59745-401-x:423.
- MIF "Rediscovered"Bucala R. MIF "Rediscovered". 2007, 19-34. DOI: 10.1142/9789812775917_0002.
- 1622: Macrophage Migration Inhibitory Factor (MIF) Gene Polymorphisms are Associated with Susceptibility and Severity of Prostate CancerMeyer-Siegler K, Vera P, Iczkowski K, Bifulco C, Lee A, Gregersen P, Leng L, Bucala R. 1622: Macrophage Migration Inhibitory Factor (MIF) Gene Polymorphisms are Associated with Susceptibility and Severity of Prostate Cancer. Investigative Urology 2007, 177: 537-538. DOI: 10.1016/s0022-5347(18)31810-x.
- Fibrocytes: Discovery of a Circulating Connective Tissue Cell ProgenitorBucala R. Fibrocytes: Discovery of a Circulating Connective Tissue Cell Progenitor. 2007, 1-18. DOI: 10.1142/9789812706690_0001.
- The Role of Macrophage Migration Inhibitory Factor (MIF) Genetic Polymorphisms in Predicting the Development of Macrocytic Anemia in HIV+ Patients.Lin S, Fultz S, Justice A, Bucala R, Vanasse K, Berliner N. The Role of Macrophage Migration Inhibitory Factor (MIF) Genetic Polymorphisms in Predicting the Development of Macrocytic Anemia in HIV+ Patients. Blood 2006, 108: 1254-1254. DOI: 10.1182/blood.v108.11.1254.1254.
- Immunosuppressive Factors in CancerMoss J, Metz C, Bucala R. Immunosuppressive Factors in Cancer. 2006 DOI: 10.1002/3527600906.mcb.200400129.
- MIF and the Genetic Basis of Macrophage ResponsivenessBucala R. MIF and the Genetic Basis of Macrophage Responsiveness. Current Immunology Reviews 2006, 2: 217-223. DOI: 10.2174/157339506778018569.
- 634: Mice with a Null Mutation For Macrophage Migration Inhibitory Factor Have Lower Stage Tumors in a Mouse Model of Bladder CancerTaylor J, Kuchel G, Hegde P, Voznesensky O, Sasso D, Claffey K, Bucala R, Pilbeam C. 634: Mice with a Null Mutation For Macrophage Migration Inhibitory Factor Have Lower Stage Tumors in a Mouse Model of Bladder Cancer. Investigative Urology 2006, 175: 204. DOI: 10.1016/s0022-5347(18)32880-5.
- Tu-P10:495 Serum level of soluble receptor for advanced glycation end products is associated with circulating advanced glycation end products in type 2 diabetesTan K, Chow W, Shiu S, Bucala R, Betteridge D. Tu-P10:495 Serum level of soluble receptor for advanced glycation end products is associated with circulating advanced glycation end products in type 2 diabetes. Atherosclerosis Plus 2006, 7: 294. DOI: 10.1016/s1567-5688(06)81196-7.
- 141: Macrophage Migration Inhibitory Factor Mediates Smooth Muscle Death in Bladder Outlet ObstructionTaylor J, Zhu Q, Sasso D, Pilbeam C, Leng L, Bucala R, Kuchel G. 141: Macrophage Migration Inhibitory Factor Mediates Smooth Muscle Death in Bladder Outlet Obstruction. Investigative Urology 2005, 173: 38. DOI: 10.1016/s0022-5347(18)34406-9.
- 1409: Further Evidence for an Association between Macrophage Migration Inhibitory Factor and Prostate CancerMeyer-Siegler K, Iczkowski K, Leng L, Bucala R, Vera P. 1409: Further Evidence for an Association between Macrophage Migration Inhibitory Factor and Prostate Cancer. Investigative Urology 2005, 173: 382. DOI: 10.1016/s0022-5347(18)35543-5.
- Identification of 2-Lactylamido-Guanine (LAG) as a DNA-Advanced Glycosylation EndproductPapoulis A, Cerami A, Bucala R. Identification of 2-Lactylamido-Guanine (LAG) as a DNA-Advanced Glycosylation Endproduct. 2005, 431. DOI: 10.1533/9781845698393.8.431a.
- Glucose-mediated DNA Damage and Mutations: In Vitro and In VivoLee A, Cerami A, Bucala R. Glucose-mediated DNA Damage and Mutations: In Vitro and In Vivo. 2005, 249-253. DOI: 10.1533/9781845698393.4.249.
- A NOVEL AGE CROSSLINK EXHIBITING IMMUNOLOGICAL CROSS-REACTIVITY WITH AGES FORMED IN VIVOAl-Abed Y, Bucala R. A NOVEL AGE CROSSLINK EXHIBITING IMMUNOLOGICAL CROSS-REACTIVITY WITH AGES FORMED IN VIVO. 2005, 239-244. DOI: 10.1533/9781845698447.7.239.
- Advanced Glycosylation of LDL: Role in Oxidative Modification and Diabetic ComplicationsBucala R, Makita Z, Cerami A, Vlassara H, Koschinsky T. Advanced Glycosylation of LDL: Role in Oxidative Modification and Diabetic Complications. 2005, 286-291. DOI: 10.1533/9781845698393.4.286.
- Aminoguanidine Decreases Atherosclerotic Plaque Formation in the Cholesterol-Fed RabbitPanagiotopoulos S, O'Brien R, Cooper M, Jerums G, Bucala R. Aminoguanidine Decreases Atherosclerotic Plaque Formation in the Cholesterol-Fed Rabbit. 2005, 426. DOI: 10.1533/9781845698393.7.426a.
- Macrophage Migration Inhibitory Factor (MIF)-Deficient MiceFingerle-Rowson G, Satoskar A, Bucala R. Macrophage Migration Inhibitory Factor (MIF)-Deficient Mice. 2003, 0: 361-378. DOI: 10.1385/1-59259-405-0:361.
- Macrophage Migration Inhibitory Factor (MIF)Bucala R. Macrophage Migration Inhibitory Factor (MIF). 2003, 617-622. DOI: 10.1016/b0-12-341103-3/00201-1.
- Chapter 45 Macrophage migration inhibitory factor (MIF)Arenberg D, Bucala R. Chapter 45 Macrophage migration inhibitory factor (MIF). 2003, II: 1037-xxxiii. DOI: 10.1016/b978-012689663-3/50049-1.
- Plasma concentrations of macrophage migration inhibitory factor are elevated in Pima Indians compared to Caucasians and are associated with insulin resistanceVozarova B, Metz C, Stefan N, Hanson R, Lindsay R, Bucala R, Bogardus C, Tataranni P. Plasma concentrations of macrophage migration inhibitory factor are elevated in Pima Indians compared to Caucasians and are associated with insulin resistance. Diabetologia 2002, 45: 1739-1741. PMID: 12552367, DOI: 10.1007/s00125-002-0896-4.
- New horizons in AGE researchBucala R. New horizons in AGE research. International Congress Series 2002, 1245: 113-117. DOI: 10.1016/s0531-5131(02)00886-5.
- Immunosuppresive Factors in CancerBucala R, Metz C. Immunosuppresive Factors in Cancer. 2002, 119-154. DOI: 10.1002/3527600795.ch7.
- Macrophage Migration Inhibitory Factor (MIF)Calandra T, Bucala R. Macrophage Migration Inhibitory Factor (MIF). 2002 DOI: 10.1002/0471203076.emm0331.
- Peripheral Blood FibrocytesChesney J, Bucala R. Peripheral Blood Fibrocytes. 2002, 5: 209-219. DOI: 10.1007/0-306-46870-0_10.
- Structure activity studies of macrophage migration inhibitory factor show a functional role for cysteine residuesBernhagen J, Kleemann R, Kapurniotu A, Bucala R, Brunner H. Structure activity studies of macrophage migration inhibitory factor show a functional role for cysteine residues. 2002, 5: 400-401. DOI: 10.1007/0-306-46862-x_170.
- Identification of a minimal peptide sequence of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic propertiesKapurniotu A, Bernhagen J, Fischle W, Teichberg S, Voelter W, Bucala R. Identification of a minimal peptide sequence of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties. 2002, 5: 394-395. DOI: 10.1007/0-306-46862-x_167.
- Macrophage Migration Inhibitory Factor: A Critical Neurohumoral MediatorPetrovsky N, Bucala R. Macrophage Migration Inhibitory Factor: A Critical Neurohumoral Mediator. 2002, 29: 83-90. PMID: 11789350, DOI: 10.1159/000061060.
- Up‐regulation of macrophage migration inhibitory factor in acute renal allograft rejection in the ratBrown, Nikolic‐Paterson, Metz, Bucala, Atkins, Lan. Up‐regulation of macrophage migration inhibitory factor in acute renal allograft rejection in the rat. Clinical & Experimental Immunology 2001, 118: 329-336. PMID: 10540199, PMCID: PMC1905421, DOI: 10.1046/j.1365-2249.1999.01048.x.
- Lysozyme Enhances Renal Excretion of Advanced Glycation Endproducts In Vivo and Suppresses Adverse AGE-mediated Cellular Effects In Vitro: A Potential AGE Sequestration Therapy for Diabetic Nephropathy?Zheng F, Cai W, Mitsuhashi T, Vlassara H, Bucala R. Lysozyme Enhances Renal Excretion of Advanced Glycation Endproducts In Vivo and Suppresses Adverse AGE-mediated Cellular Effects In Vitro: A Potential AGE Sequestration Therapy for Diabetic Nephropathy? Molecular Medicine 2001, 7: 737-747. PMID: 11788787, PMCID: PMC1950004, DOI: 10.1007/bf03401963.
- Immunological Detection of a Novel Advanced Glycation End-ProductTakeuchi M, Yanase Y, Matsuura N, Yamagishi S, Kameda Y, Bucala R, Makita Z. Immunological Detection of a Novel Advanced Glycation End-Product. Molecular Medicine 2001, 7: 783-791. PMID: 11788793, PMCID: PMC1950006, DOI: 10.1007/bf03401969.
- Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivoHartlapp I, Abe R, Saeed R, Peng T, Voelter W, Bucala R, Metz C. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. The FASEB Journal 2001, 15: 2215-2224. PMID: 11641248, DOI: 10.1096/fj.01-0049com.
- Macrophage migration inhibitory factor is an important mediator in the pathogenesis of gastric inflammation in ratsHuang X, Hui C, Chen Y, Chun B, Wong Y, Fung P, Metz C, Cho C, Hui W, Bucala R, Lam S, Lan H. Macrophage migration inhibitory factor is an important mediator in the pathogenesis of gastric inflammation in rats. Gastroenterology 2001, 121: 619-630. PMID: 11522746, DOI: 10.1053/gast.2001.27205.
- Characterization of a Novel Hemoglobin-Glutathione Adduct That Is Elevated in Diabetic PatientsAl-Abed Y, VanPatten S, Li H, Lawson J, FitzGerald G, Manogue K, Bucala R. Characterization of a Novel Hemoglobin-Glutathione Adduct That Is Elevated in Diabetic Patients. Molecular Medicine 2001, 7: 619-623. PMID: 11778651, PMCID: PMC1950073, DOI: 10.1007/bf03401868.
- Neuroendocrine properties of macrophage migration inhibitory factor (MIF)Fingerle‐Rowson G, Bucala R. Neuroendocrine properties of macrophage migration inhibitory factor (MIF). Immunology And Cell Biology 2001, 79: 368-375. PMID: 11488984, DOI: 10.1046/j.1440-1711.2001.01024.x.
- Peripheral Blood Fibrocytes: Differentiation Pathway and Migration to Wound SitesAbe R, Donnelly S, Peng T, Bucala R, Metz C. Peripheral Blood Fibrocytes: Differentiation Pathway and Migration to Wound Sites. The Journal Of Immunology 2001, 166: 7556-7562. PMID: 11390511, DOI: 10.4049/jimmunol.166.12.7556.
- URINE MACROPHAGE MIGRATION INHIBITORY FACTOR CONCENTRATIONS AS A DIAGNOSTIC TOOL IN HUMAN RENAL ALLOGRAFT REJECTION1Brown F, Nikolic-Paterson D, Chadban S, Dowling J, Jose M, Metz C, Bucala R, Atkins R. URINE MACROPHAGE MIGRATION INHIBITORY FACTOR CONCENTRATIONS AS A DIAGNOSTIC TOOL IN HUMAN RENAL ALLOGRAFT REJECTION1. Transplantation 2001, 71: 1777-1783. PMID: 11455258, DOI: 10.1097/00007890-200106270-00013.
- Regulation of the CTL Response by Macrophage Migration Inhibitory FactorAbe R, Peng T, Sailors J, Bucala R, Metz C. Regulation of the CTL Response by Macrophage Migration Inhibitory Factor. The Journal Of Immunology 2001, 166: 747-753. PMID: 11145646, DOI: 10.4049/jimmunol.166.2.747.
- Purification and Characterization of Macrophage Migration Inhibitory Factor as a Secretory Protein from Rat Epididymis: Evidences for Alternative Release and Transfer to SpermatozoaEickhoff R, Wilhelm B, Renneberg H, Wennemuth G, Bacher M, Linder D, Bucala R, Seitz J, Meinhardt A. Purification and Characterization of Macrophage Migration Inhibitory Factor as a Secretory Protein from Rat Epididymis: Evidences for Alternative Release and Transfer to Spermatozoa. Molecular Medicine 2001, 7: 27-35. PMID: 11474125, PMCID: PMC1949991, DOI: 10.1007/bf03401836.
- De Novo Expression of Macrophage Migration Inhibitory Factor in Atherogenesis in RabbitsLin S, Yu X, Chen Y, Huang X, Metz C, Bucala R, Lau C, Lan H. De Novo Expression of Macrophage Migration Inhibitory Factor in Atherogenesis in Rabbits. Circulation Research 2000, 87: 1202-1208. PMID: 11110779, DOI: 10.1161/01.res.87.12.1202.
- Peripheral blood fibrocytes: Mesenchymal precursor cells and the pathogenesis of fibrosisChesney J, Bucala R. Peripheral blood fibrocytes: Mesenchymal precursor cells and the pathogenesis of fibrosis. Current Rheumatology Reports 2000, 2: 501-505. PMID: 11123104, DOI: 10.1007/s11926-000-0027-5.
- Neurotoxicity of Advanced Glycation End-Products for Cultured Cortical NeuronsTakeuchi M, Bucala R, Suzuki T, Ohkubo T, Yamazaki M, Koike T, Kameda Y, Makita Z. Neurotoxicity of Advanced Glycation End-Products for Cultured Cortical Neurons. Journal Of Neuropathology & Experimental Neurology 2000, 59: 1094-1105. PMID: 11138929, DOI: 10.1093/jnen/59.12.1094.
- The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscleBenigni F, Atsumi T, Calandra T, Metz C, Echtenacher B, Peng T, Bucala R. The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. Journal Of Clinical Investigation 2000, 106: 1291-1300. PMID: 11086030, PMCID: PMC381433, DOI: 10.1172/jci9900.
- A most interesting factorBucala R. A most interesting factor. Nature 2000, 408: 146-147. PMID: 11089953, DOI: 10.1038/35041654.
- URINARY macrophage migration inhibitory factor (MIF) LEVELS REFLECT RENAL INFLAMMATION IN HUMAN GNFg B, Dj N, Nm I, Bucala R, Metz C, Jp D, Atkins R. URINARY macrophage migration inhibitory factor (MIF) LEVELS REFLECT RENAL INFLAMMATION IN HUMAN GN. Nephrology 2000, 5: a95-a95. DOI: 10.1046/j.1440-1797.2000.abs26.x.
- URINE MIF LEVELS DISCRIMINATE BETWEEN HUMAN RENAL ALLOGRAFT REJECTION AND CYCLOSPORINE NEPHROTOXICITYFg B, Dj N, Sj C, Cn M, Bucala R, Jp D, Atkins R. URINE MIF LEVELS DISCRIMINATE BETWEEN HUMAN RENAL ALLOGRAFT REJECTION AND CYCLOSPORINE NEPHROTOXICITY. Nephrology 2000, 5: a98-a98. DOI: 10.1046/j.1440-1797.2000.abs41.x.
- URINARY macrophage migration inhibitory factor (MIF) LEVELS REFLECT RENAL INFLAMMATION IN HUMAN GNFg B, Dj N, Nm I, Bucala R, Metz C, Jp D, Atkins R. URINARY macrophage migration inhibitory factor (MIF) LEVELS REFLECT RENAL INFLAMMATION IN HUMAN GN. Nephrology 2000, 5: a95-a95. DOI: 10.1046/j.1440-1797.2000.abs114.x.
- URINE MIF LEVELS DISCRIMINATE BETWEEN HUMAN RENAL ALLOGRAFT REJECTION AND CYCLOSPORINE NEPHROTOXICITYFg B, Dj N, Sj C, Cn M, Bucala R, Jp D, Atkins R. URINE MIF LEVELS DISCRIMINATE BETWEEN HUMAN RENAL ALLOGRAFT REJECTION AND CYCLOSPORINE NEPHROTOXICITY. Nephrology 2000, 5: a98-a98. DOI: 10.1046/j.1440-1797.2000.abs128.x.
- Expression of macrophage migration inhibitory factor in human glomerulonephritisLan H, Yang N, Nikolic-Paterson D, Yu X, Mu W, Isbel N, Metz C, Bucala R, Atkins R. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney International 2000, 57: 499-509. PMID: 10652026, DOI: 10.1046/j.1523-1755.2000.00869.x.
- Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF)Mitchell R, Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Seminars In Cancer Biology 2000, 10: 359-366. PMID: 11100884, DOI: 10.1006/scbi.2000.0328.
- Involvement of Macrophage Migration Inhibitory Factor (MIF) in Experimental Uric Acid NephropathyKim Y, Huang X, Suga S, Mazzali M, Tang D, Metz C, Bucala R, Kivlighn S, Johnson R, Lan H. Involvement of Macrophage Migration Inhibitory Factor (MIF) in Experimental Uric Acid Nephropathy. Molecular Medicine 2000, 6: 837-848. PMID: 11126199, PMCID: PMC1949919, DOI: 10.1007/bf03401822.
- Macaque blood‐derived antigen‐presenting cells elicit SIV‐specific immune responsesZhu Y, Koo K, Bradshaw J, Sutton W, Kuller L, Bucala R, Anderson D, Mossman S, Villinger F, Haigwood N. Macaque blood‐derived antigen‐presenting cells elicit SIV‐specific immune responses. Journal Of Medical Primatology 2000, 29: 182-192. PMID: 11085581, DOI: 10.1034/j.1600-0684.2000.290312.x.
- Macrophage Migration Inhibitory Factor Release by Macrophages after Ingestion of Plasmodium chabaudi-Infected Erythrocytes: Possible Role in the Pathogenesis of Malarial AnemiaMartiney J, Sherry B, Metz C, Espinoza M, Ferrer A, Calandra T, Broxmeyer H, Bucala R. Macrophage Migration Inhibitory Factor Release by Macrophages after Ingestion of Plasmodium chabaudi-Infected Erythrocytes: Possible Role in the Pathogenesis of Malarial Anemia. Infection And Immunity 2000, 68: 2259-2267. PMID: 10722628, PMCID: PMC97412, DOI: 10.1128/iai.68.4.2259-2267.2000.
- Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant‐induced arthritisLeech M, Metz C, Bucala R, MorAnd E. Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant‐induced arthritis. Arthritis & Rheumatism 2000, 43: 827-833. PMID: 10765927, DOI: 10.1002/1529-0131(200004)43:4<827::aid-anr13>3.0.co;2-k.
- Protection from septic shock by neutralization of macrophage migration inhibitory factorCalandra T, Echtenacher B, Roy D, Pugin J, Metz C, Hültner L, Heumann D, Männel D, Bucala R, Glauser M. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nature Medicine 2000, 6: 164-170. PMID: 10655104, DOI: 10.1038/72262.
- Immunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivoTakeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivo. Molecular Medicine 2000, 6: 114-125. PMID: 10859028, PMCID: PMC1949938, DOI: 10.1007/bf03401779.
- Advanced Glycosylation Endproducts and Diabetic Vascular DiseaseBucala R. Advanced Glycosylation Endproducts and Diabetic Vascular Disease. 2000, 224: 287-303. DOI: 10.1007/978-1-4615-4649-8_15.
- Macrophage Migration Inhibitory Factor (MIF): A Critical Neurohumoral MediatorPETROVSKY N, BUCALA R. Macrophage Migration Inhibitory Factor (MIF): A Critical Neurohumoral Mediator. Annals Of The New York Academy Of Sciences 2000, 917: 665-671. PMID: 11268395, DOI: 10.1111/j.1749-6632.2000.tb05432.x.
- Structure of a Synthetic Glucose Derived Advanced Glycation End Product That Is Immunologically Cross-Reactive with Its Naturally Occurring Counterparts †Al-Abed Y, Bucala R. Structure of a Synthetic Glucose Derived Advanced Glycation End Product That Is Immunologically Cross-Reactive with Its Naturally Occurring Counterparts †. Bioconjugate Chemistry 1999, 11: 39-45. PMID: 10639083, DOI: 10.1021/bc990061q.
- Peripheral blood fibrocytes with foamy virus infection-like morphologyGrab D, Lanners H, Williams W, Bucala R. Peripheral blood fibrocytes with foamy virus infection-like morphology. Human Pathology 1999, 30: 1395-1396. PMID: 10571524, DOI: 10.1016/s0046-8177(99)90076-x.
- Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity by dopachrome analogsZhang X, Bucala R. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity by dopachrome analogs. Bioorganic & Medicinal Chemistry Letters 1999, 9: 3193-3198. PMID: 10576686, DOI: 10.1016/s0960-894x(99)00561-2.
- Sequencing of Genomic DNAMahlknecht U, Hoelzer D, Bucala R. Sequencing of Genomic DNA. BioTechniques 1999, 27: 406-408. PMID: 10489593, DOI: 10.2144/99273bm01.
- Cloning and Characterization of the Murine Histone Deacetylase (HDAC3)Mahlknecht U, Hoelzer D, Bucala R, Verdin E. Cloning and Characterization of the Murine Histone Deacetylase (HDAC3). Biochemical And Biophysical Research Communications 1999, 263: 482-490. PMID: 10491319, DOI: 10.1006/bbrc.1999.1389.
- Macrophage migration inhibitory factor in rheumatoid arthritis: Evidence of proinflammatory function and regulation by glucocorticoidsLeech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, Weedon H, Holdsworth S, Bucala R, Morand E. Macrophage migration inhibitory factor in rheumatoid arthritis: Evidence of proinflammatory function and regulation by glucocorticoids. Arthritis & Rheumatism 1999, 42: 1601-1608. PMID: 10446857, DOI: 10.1002/1529-0131(199908)42:8<1601::aid-anr6>3.0.co;2-b.
- Detoxification of Methylglyoxal by the Nucleophilic Bidentate, Phenylacylthiazolium BromideFerguson G, VanPatten S, Bucala R, Al-Abed Y. Detoxification of Methylglyoxal by the Nucleophilic Bidentate, Phenylacylthiazolium Bromide. Chemical Research In Toxicology 1999, 12: 617-622. PMID: 10409401, DOI: 10.1021/tx990007y.
- Sustained Mitogen-activated Protein Kinase (MAPK) and Cytoplasmic Phospholipase A2 Activation by Macrophage Migration Inhibitory Factor (MIF) REGULATORY ROLE IN CELL PROLIFERATION AND GLUCOCORTICOID ACTION*Mitchell R, Metz C, Peng T, Bucala R. Sustained Mitogen-activated Protein Kinase (MAPK) and Cytoplasmic Phospholipase A2 Activation by Macrophage Migration Inhibitory Factor (MIF) REGULATORY ROLE IN CELL PROLIFERATION AND GLUCOCORTICOID ACTION*. Journal Of Biological Chemistry 1999, 274: 18100-18106. PMID: 10364264, DOI: 10.1074/jbc.274.25.18100.
- A Polyhydroxylated Cyclopentene: A Useful Synthon toward the Synthesis of Carbocyclic D-FructofuranoidSeepersaud M, Bucala R, Al-Abed Y. A Polyhydroxylated Cyclopentene: A Useful Synthon toward the Synthesis of Carbocyclic D-Fructofuranoid. Zeitschrift Für Naturforschung B 1999, 54: 565-568. DOI: 10.1515/znb-1999-0422.
- An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: Role in tumor cell glycolysis and the Warburg effectChesney J, Mitchell R, Benigni F, Bacher M, Spiegel L, Al-Abed Y, Han J, Metz C, Bucala R. An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: Role in tumor cell glycolysis and the Warburg effect. Proceedings Of The National Academy Of Sciences Of The United States Of America 1999, 96: 3047-3052. PMID: 10077634, PMCID: PMC15892, DOI: 10.1073/pnas.96.6.3047.
- Inhibition of advanced glycation endproduct formation by acetaldehyde: Role in the cardioprotective effect of ethanolAl-Abed Y, Mitsuhashi T, Li H, Lawson J, FitzGerald G, Founds H, Donnelly T, Cerami A, Ulrich P, Bucala R. Inhibition of advanced glycation endproduct formation by acetaldehyde: Role in the cardioprotective effect of ethanol. Proceedings Of The National Academy Of Sciences Of The United States Of America 1999, 96: 2385-2390. PMID: 10051651, PMCID: PMC26793, DOI: 10.1073/pnas.96.5.2385.
- An Essential Role for Macrophage Migration Inhibitory Factor (MIF) in Angiogenesis and the Growth of a Murine LymphomaChesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R. An Essential Role for Macrophage Migration Inhibitory Factor (MIF) in Angiogenesis and the Growth of a Murine Lymphoma. Molecular Medicine 1999, 5: 181-191. PMID: 10404515, PMCID: PMC2230298, DOI: 10.1007/bf03402061.
- Interaction of Borrelia burgdorferi with Peripheral Blood Fibrocytes, Antigen-Presenting Cells with the Potential for Connective Tissue TargetingGrab D, Lanners H, Martin L, Chesney J, Cai C, Adkisson H, Bucala R. Interaction of Borrelia burgdorferi with Peripheral Blood Fibrocytes, Antigen-Presenting Cells with the Potential for Connective Tissue Targeting. Molecular Medicine 1999, 5: 46-54. PMID: 10072447, PMCID: PMC2230375, DOI: 10.1007/bf03402138.
- A role for the endocrine and pro‐inflammatory mediator MIF in the control of insulin secretion during stressWaeber G, Calandra T, Bonny C, Bucala R. A role for the endocrine and pro‐inflammatory mediator MIF in the control of insulin secretion during stress. Diabetes/Metabolism Research And Reviews 1999, 15: 47-54. PMID: 10398546, DOI: 10.1002/(sici)1520-7560(199901/02)15:1<47::aid-dmrr9>3.0.co;2-j.
- Filarial nematode parasites secrete a homologue of the human cytokine macrophage migration inhibitory factor.Pastrana D, Raghavan N, FitzGerald P, Eisinger S, Metz C, Bucala R, Schleimer R, Bickel C, Scott A. Filarial nematode parasites secrete a homologue of the human cytokine macrophage migration inhibitory factor. Infection And Immunity 1998, 66: 5955-63. PMID: 9826378, PMCID: PMC108754, DOI: 10.1128/iai.66.12.5955-5963.1998.
- Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteriaCalandra T, Spiegel L, Metz C, Bucala R. Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 11383-11388. PMID: 9736745, PMCID: PMC21651, DOI: 10.1073/pnas.95.19.11383.
- Increased Levels of Advanced Glycation Endproducts in the Lenses and Blood Vessels of Cigarette SmokersNicholl I, Stitt A, Moore J, Ritchie A, Archer D, Bucala R. Increased Levels of Advanced Glycation Endproducts in the Lenses and Blood Vessels of Cigarette Smokers. Molecular Medicine 1998, 4: 594-601. PMID: 9848076, PMCID: PMC2230315, DOI: 10.1007/bf03401759.
- Local Regulation of Macrophage Subsets in the Adult Rat Testis: Examination of the Roles of the Seminiferous Tubules, Testosterone, and Macrophage-Migration Inhibitory FactorMeinhardt A, Bacher M, Metz C, Bucala R, Wreford N, Lan H, Atkins R, Hedger M. Local Regulation of Macrophage Subsets in the Adult Rat Testis: Examination of the Roles of the Seminiferous Tubules, Testosterone, and Macrophage-Migration Inhibitory Factor. Biology Of Reproduction 1998, 59: 371-378. PMID: 9687310, DOI: 10.1095/biolreprod59.2.371.
- Identification of N2-(1-carboxymethyl)guanine (CMG) as a guanine advanced glycation end productAl-Abed Y, Schleicher E, Voelter W, Liebich H, Papoulis A, Bucala R. Identification of N2-(1-carboxymethyl)guanine (CMG) as a guanine advanced glycation end product. Bioorganic & Medicinal Chemistry Letters 1998, 8: 2109-2110. PMID: 9873495, DOI: 10.1016/s0960-894x(98)00398-9.
- Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end productsWang X, Bucala R, Milne R. Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products. Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 7643-7647. PMID: 9636203, PMCID: PMC22709, DOI: 10.1073/pnas.95.13.7643.
- Reversal of Established Rat Crescentic Glomerulonephritis by Blockade of Macrophage Migration Inhibitory Factor (MIF): Potential Role of MIF in Regulating Glucocorticoid ProductionYang N, Nikolic-Paterson D, Ng Y, Mu W, Metz C, Bacher M, Meinhardt A, Bucala R, Atkins R, Lan H. Reversal of Established Rat Crescentic Glomerulonephritis by Blockade of Macrophage Migration Inhibitory Factor (MIF): Potential Role of MIF in Regulating Glucocorticoid Production. Molecular Medicine 1998, 4: 413-424. PMID: 10780884, PMCID: PMC2230272, DOI: 10.1007/bf03401748.
- Advanced Glycation End Products Increase Retinal Vascular Endothelial Growth Factor Expression.Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R, Adamis A. Advanced Glycation End Products Increase Retinal Vascular Endothelial Growth Factor Expression. Retina 1998, 18: 491. DOI: 10.1097/00006982-199805000-00030.
- Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritisLeech M, Metz C, Santos L, Peng T, Holdsworth S, Bucala R, Morand E. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis & Rheumatism 1998, 41: 910-917. PMID: 9588744, DOI: 10.1002/1529-0131(199805)41:5<910::aid-art19>3.0.co;2-e.
- Neuroimmunomodulation by Macrophage Migration Inhibitory Factor (MIF)BUCALA R. Neuroimmunomodulation by Macrophage Migration Inhibitory Factor (MIF). Annals Of The New York Academy Of Sciences 1998, 840: 74-82. PMID: 9629239, DOI: 10.1111/j.1749-6632.1998.tb09551.x.
- Advanced Glycation Endproducts in Neurofilament Conglomeration of Motoneurons in Familial and Sporadic Amyotrophic Lateral SclerosisChou S, Wang H, Taniguchi A, Bucala R. Advanced Glycation Endproducts in Neurofilament Conglomeration of Motoneurons in Familial and Sporadic Amyotrophic Lateral Sclerosis. Molecular Medicine 1998, 4: 324-332. PMID: 9642682, PMCID: PMC2230387, DOI: 10.1007/bf03401739.
- MIF Expression in the Rat Brain: Implications for Neuronal FunctionBacher M, Meinhardt A, Lan H, Dhabhar F, Mu W, Metz C, Chesney J, Gemsa D, Donnelly T, Atkins R, Bucala R. MIF Expression in the Rat Brain: Implications for Neuronal Function. Molecular Medicine 1998, 4: 217-230. PMID: 9606175, PMCID: PMC2230367, DOI: 10.1007/bf03401919.
- Role of cyclophilin A in the uptake of HIV-1 by macrophages and T lymphocytesSherry B, Zybarth G, Alfano M, Dubrovsky L, Mitchell R, Rich D, Ulrich P, Bucala R, Cerami A, Bukrinsky M. Role of cyclophilin A in the uptake of HIV-1 by macrophages and T lymphocytes. Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 1758-1763. PMID: 9465090, PMCID: PMC19180, DOI: 10.1073/pnas.95.4.1758.
- Regulation of the immune response by macrophage migration inhibitory factor: biological and structural featuresBernhagen J, Calandra T, Bucala R. Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features. Journal Of Molecular Medicine 1998, 76: 151-161. PMID: 9535548, DOI: 10.1007/s001090050204.
- Protein Glycation and Diabetic Vascular DiseaseBucala R, Rahbar S. Protein Glycation and Diabetic Vascular Disease. 1998, 1: 159-180. DOI: 10.1007/978-1-4615-5569-8_9.
- Chapter 24 Macrophage Migration Inhibitory Factor (MIF): A Critical Upstream Regulator of Acute and Chronic Inflammatory ResponsesRice G, Liittschwager K, Metz C, Bucala R. Chapter 24 Macrophage Migration Inhibitory Factor (MIF): A Critical Upstream Regulator of Acute and Chronic Inflammatory Responses. 1998, 33: 243-252. DOI: 10.1016/s0065-7743(08)61089-1.
- Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptideKapurniotu A, Bernhagen J, Greenfield N, Al‐Abed Y, Teichberg S, Frank R, Voelter W, Bucala R. Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide. The FEBS Journal 1998, 251: 208-216. PMID: 9492286, DOI: 10.1046/j.1432-1327.1998.2510208.x.
- Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbitPanagiotopoulos S, O'Brien R, Bucala R, Cooper M, Jerums G. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis 1998, 136: 125-131. PMID: 9544739, DOI: 10.1016/s0021-9150(97)00192-5.
- Tobacco smoke is a source of toxic reactive glycation productsCerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R, Cerami A. Tobacco smoke is a source of toxic reactive glycation products. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 13915-13920. PMID: 9391127, PMCID: PMC28407, DOI: 10.1073/pnas.94.25.13915.
- Biochemical and Mutational Investigations of the Enzymatic Activity of Macrophage Migration Inhibitory Factor †Bendrat K, Al-Abed Y, Callaway D, Peng T, Calandra T, Metz C, Bucala R. Biochemical and Mutational Investigations of the Enzymatic Activity of Macrophage Migration Inhibitory Factor †. Biochemistry 1997, 36: 15356-15362. PMID: 9398265, DOI: 10.1021/bi971153a.
- Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremiaFishbane S, Bucala R, Pereira B, Founds H, Vlassara H. Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney International 1997, 52: 1645-1650. PMID: 9407512, DOI: 10.1038/ki.1997.497.
- Molecular Characterization of a Mouse Genomic Element Mobilized by Advanced Glycation Endproduct Modified-DNA (AGE-DNA)Pushkarsky T, Rourke L, Spiegel L, Seldin M, Bucala R. Molecular Characterization of a Mouse Genomic Element Mobilized by Advanced Glycation Endproduct Modified-DNA (AGE-DNA). Molecular Medicine 1997, 3: 740-749. PMID: 9407550, PMCID: PMC2230240, DOI: 10.1007/bf03401712.
- Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory diseaseDonnelly S, Bucala R. Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease. Trends In Molecular Medicine 1997, 3: 502-507. PMID: 9430786, DOI: 10.1016/s1357-4310(97)01133-7.
- Elevated AGE-Modified ApoB in Sera of Euglycemic, Normolipidemic Patients with Atherosclerosis: Relationship to Tissue AGEsStitt A, He C, Friedman S, Scher L, Rossi P, Ong L, Founds H, Li Y, Bucala R, Vlassara H. Elevated AGE-Modified ApoB in Sera of Euglycemic, Normolipidemic Patients with Atherosclerosis: Relationship to Tissue AGEs. Molecular Medicine 1997, 3: 617-627. PMID: 9323713, PMCID: PMC2230092, DOI: 10.1007/bf03401819.
- A switch in the cellular localization of macrophage migration inhibitory factor (MIF) in rat testis after ethane dimethane sulfonate treatmentMeinhardt A, Bacher M, McFarlane J, Mallidis C, Lehmann C, Metz C, de Kretser D, Bucala R, Hedger M. A switch in the cellular localization of macrophage migration inhibitory factor (MIF) in rat testis after ethane dimethane sulfonate treatment. Journal Of Reproductive Immunology 1997, 34: 35-36. DOI: 10.1016/s0165-0378(97)90404-6.
- Efficient Scavenging of Fatty Acid Oxidation Products by AminoguanidineAl-Abed Y, Bucala R. Efficient Scavenging of Fatty Acid Oxidation Products by Aminoguanidine. Chemical Research In Toxicology 1997, 10: 875-879. PMID: 9282836, DOI: 10.1021/tx970035l.
- The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situChesney J, Bacher M, Bender A, Bucala R. The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 6307-6312. PMID: 9177213, PMCID: PMC21045, DOI: 10.1073/pnas.94.12.6307.
- Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathyKoschinsky T, He C, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 6474-6479. PMID: 9177242, PMCID: PMC21074, DOI: 10.1073/pnas.94.12.6474.
- Insulin secretion is regulated by the glucose-dependent production of islet β cell macrophage migration inhibitory factorWaeber G, Calandra T, Roduit R, Haefliger J, Bonny C, Thompson N, Thorens B, Temler E, Meinhardt A, Bacher M, Metz C, Nicod P, Bucala R. Insulin secretion is regulated by the glucose-dependent production of islet β cell macrophage migration inhibitory factor. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 4782-4787. PMID: 9114069, PMCID: PMC20802, DOI: 10.1073/pnas.94.9.4782.
- The Pathogenic Role of Macrophage Migration Inhibitory Factor in Immunologically Induced Kidney Disease in the RatLan H, Bacher M, Yang N, Mu W, Nikolic-Paterson D, Metz C, Meinhardt A, Bucala R, Atkins R. The Pathogenic Role of Macrophage Migration Inhibitory Factor in Immunologically Induced Kidney Disease in the Rat. Journal Of Experimental Medicine 1997, 185: 1455-1466. PMID: 9126926, PMCID: PMC2196273, DOI: 10.1084/jem.185.8.1455.
- Atherogenesis and Advanced Glycation: Promotion, Progression, and PreventionaSTITT A, BUCALA R, VLASSARA H. Atherogenesis and Advanced Glycation: Promotion, Progression, and Preventiona. Annals Of The New York Academy Of Sciences 1997, 811: 115-129. PMID: 9186590, DOI: 10.1111/j.1749-6632.1997.tb51994.x.
- Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndromeDonnelly S, Haslett C, Reid P, Grant I, Wallace W, Metz C, Bruce L, Bucala R. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nature Medicine 1997, 3: 320-323. PMID: 9055860, DOI: 10.1038/nm0397-320.
- TNF-α Up-regulates Renal MIF Expression in Rat Crescentic GlomerulonephritisLan H, Yang N, Metz C, Mu W, Song Q, Nikolic-Paterson D, Bacher M, Bucala R, Atkins R. TNF-α Up-regulates Renal MIF Expression in Rat Crescentic Glomerulonephritis. Molecular Medicine 1997, 3: 136-144. PMID: 9085256, PMCID: PMC2230061, DOI: 10.1007/bf03401805.
- Lipoprotein Modification by Advanced Glycosylation Endproducts (AGEs): Role in AtherosclerosisBucala R. Lipoprotein Modification by Advanced Glycosylation Endproducts (AGEs): Role in Atherosclerosis. Trends In Cardiovascular Medicine 1997, 7: 39-47. PMID: 21235862, DOI: 10.1016/s1050-1738(96)00137-5.
- Macrophage Migration Inhibitory Factor (MIF): A Glucocorticoid Counter-Regulator within the Immune SystemCalandra T, Bucala R. Macrophage Migration Inhibitory Factor (MIF): A Glucocorticoid Counter-Regulator within the Immune System. Critical Reviews In Immunology 1997, 17: 77-88. PMID: 9034724, DOI: 10.1615/critrevimmunol.v17.i1.30.
- Role of Macrophage Migration Inhibitory Factor in the Regulation of the Immune ResponseMetz C, Bucala R. Role of Macrophage Migration Inhibitory Factor in the Regulation of the Immune Response. 1997, 66: 197-223. PMID: 9328642, DOI: 10.1016/s0065-2776(08)60598-2.
- MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid‐induced regulator of the immune responseBucala R. MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid‐induced regulator of the immune response. The FASEB Journal 1996, 10: 1607-1613. PMID: 9002552, DOI: 10.1096/fasebj.10.14.9002552.
- Delayed‐type hypersensitivity mediates Bowman's capsule rupture in Tamm—Horsfall protein‐induced tubulointerstitial nephritis in the ratQing S, NIKOLIC‐PATERSON D, ATKINS R, BACHER M, BUCALA R, Hui Y. Delayed‐type hypersensitivity mediates Bowman's capsule rupture in Tamm—Horsfall protein‐induced tubulointerstitial nephritis in the rat. Nephrology 1996, 2: 417-427. DOI: 10.1111/j.1440-1797.1996.tb00123.x.
- Lipid and lipoprotein oxidation: basic mechanisms and unresolved questions in vivoBucala R. Lipid and lipoprotein oxidation: basic mechanisms and unresolved questions in vivo. Redox Report 1996, 2: 291-307. PMID: 27406410, DOI: 10.1080/13510002.1996.11747065.
- NMR characterization of structure, backbone dynamics, and glutathione binding of the human macrophage migration inhibitory factor (MIF)Mühlhahn P, Czisch M, Georgescu J, Renner C, Ross A, Holak T, Bernhagen J, Bucala R. NMR characterization of structure, backbone dynamics, and glutathione binding of the human macrophage migration inhibitory factor (MIF). Protein Science 1996, 5: 2095-2103. PMID: 8897610, PMCID: PMC2143260, DOI: 10.1002/pro.5560051016.
- Glycation and microglial reaction in lesions of Alzheimer's diseaseDickson D, Sinicropi S, Yen S, Ko L, Mattiace L, Bucala R, Vlassara H. Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiology Of Aging 1996, 17: 733-743. PMID: 8892346, DOI: 10.1016/0197-4580(96)00116-9.
- Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatmentSoulis T, Cooper M, Vranes D, Bucala R, Jerums G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney International 1996, 50: 627-634. PMID: 8840295, DOI: 10.1038/ki.1996.358.
- Novel modifications of Nα-boc-arginine and Nα-CBZ-lysine by methylglyoxalAl-Abed Y, Mitsuhashi T, Ulrich P, Bucala R. Novel modifications of Nα-boc-arginine and Nα-CBZ-lysine by methylglyoxal. Bioorganic & Medicinal Chemistry Letters 1996, 6: 1577-1578. DOI: 10.1016/s0960-894x(96)00276-4.
- Recent Progress in Advanced Glycation and Diabetic Vascular Disease: Role of Advanced Glycation End Product ReceptorsVlassara H, Bucala R. Recent Progress in Advanced Glycation and Diabetic Vascular Disease: Role of Advanced Glycation End Product Receptors. Diabetes 1996, 45: s65-s66. PMID: 8674896, DOI: 10.2337/diab.45.3.s65.
- An agent cleaving glucose-derived protein crosslinks in vitro and in vivoVasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996, 382: 275-278. PMID: 8717046, DOI: 10.1038/382275a0.
- MIF re-discovered: Pituitary hormone and glucocorticoid-induced regulator of cytokine productionBucala R. MIF re-discovered: Pituitary hormone and glucocorticoid-induced regulator of cytokine production. Cytokine & Growth Factor Reviews 1996, 7: 19-24. PMID: 8864351, DOI: 10.1016/1359-6101(96)00008-1.
- Hydroxyalkenal Formation Induced by Advanced Glycosylation of Low Density Lipoprotein (∗)Al-Abed Y, Bucala R, Liebich H, Voelter W. Hydroxyalkenal Formation Induced by Advanced Glycosylation of Low Density Lipoprotein (∗). Journal Of Biological Chemistry 1996, 271: 2892-2896. PMID: 8621676, DOI: 10.1074/jbc.271.6.2892.
- What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine?Bucala R. What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine? Diabetes Research And Clinical Practice 1996, 30: s157-s159. DOI: 10.1016/s0168-8227(96)80061-1.
- The subunit structure of human macrophage migration inhibitory factor: evidence for a trimerSun H, Swope M, Craig C, Bedarkar S, Bernhagen J, Bucala R, Lolis E. The subunit structure of human macrophage migration inhibitory factor: evidence for a trimer. Protein Engineering Design And Selection 1996, 9: 631-635. PMID: 8875640, DOI: 10.1093/protein/9.8.631.
- The Immunoregulatory Mediator Macrophage Migration Inhibitory Factor (MIF) Catalyzes a Tautomerization ReactionRosengren E, Bucala R, Åman P, Jacobsson L, Odh G, Metz C, Rorsman H. The Immunoregulatory Mediator Macrophage Migration Inhibitory Factor (MIF) Catalyzes a Tautomerization Reaction. Molecular Medicine 1996, 2: 143-149. PMID: 8900542, PMCID: PMC2230029, DOI: 10.1007/bf03402210.
- What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine?Bucala R. What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine? Diabetes Research And Clinical Practice 1996, 30: s123-s130. PMID: 8964186, DOI: 10.1016/s0168-8227(96)80048-9.
- Site-specific modification of apolipoprotein B by advanced glycosylation end-products: implications for lipoprotein clearance and atherogenesisBucala R. Site-specific modification of apolipoprotein B by advanced glycosylation end-products: implications for lipoprotein clearance and atherogenesis. Nephrology Dialysis Transplantation 1996, 11: 17-19. PMID: 9044301, DOI: 10.1093/ndt/11.supp5.17.
- The role of advanced glycosylation end-products in the pathogenesis of atherosclerosisMakita Z, Yanagisawa K, Kuwajima S, Bucala R, Vlassara H, Koike T. The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis. Nephrology Dialysis Transplantation 1996, 11: 31-33. PMID: 9044304, DOI: 10.1093/ndt/11.supp5.31.
- Model studies of the maillard reaction of Arg-Lys with D-riboseAl-Abed Y, Ulrich P, Kapurniotu A, Lolis E, Bucala R. Model studies of the maillard reaction of Arg-Lys with D-ribose. Bioorganic & Medicinal Chemistry Letters 1995, 5: 2929-2930. DOI: 10.1016/0960-894x(95)00513-s.
- Advanced glycosylation end products in diabetic renal and vascular diseaseBucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. American Journal Of Kidney Diseases 1995, 26: 875-888. PMID: 7503061, DOI: 10.1016/0272-6386(95)90051-9.
- Correction: MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemiaBernhagen J, Calandra T, Mitchell R, Martin S, Tracey K, Voelter W, Manogue K, Cerami A, Bucala R. Correction: MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1995, 378: 419-419. DOI: 10.1038/378419a0.
- Localization of Macrophage Migration Inhibitory Factor (MIF) to Secretory Granules within the Corticotrophic and Thyrotrophic Cells of the Pituitary GlandNishino T, Bernhagen J, Shiiki H, Calandra T, Dohi K, Bucala R. Localization of Macrophage Migration Inhibitory Factor (MIF) to Secretory Granules within the Corticotrophic and Thyrotrophic Cells of the Pituitary Gland. Molecular Medicine 1995, 1: 781-788. PMID: 8612200, PMCID: PMC2230018, DOI: 10.1007/bf03401892.
- Nε-carboxymethyllysine formation by direct addition of glyoxal to lysine during the Maillard reactionAl-Abed Y, Bucala R. Nε-carboxymethyllysine formation by direct addition of glyoxal to lysine during the Maillard reaction. Bioorganic & Medicinal Chemistry Letters 1995, 5: 2161-2162. DOI: 10.1016/0960-894x(95)00375-4.
- MIF as a glucocorticoid-induced modulator of cytokine productionCalandra T, Bernhagen J, Metz C, Spiegel L, Bacher M, Donnelly T, Cerami A, Bucala R. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377: 68-71. PMID: 7659164, DOI: 10.1038/377068a0.
- Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetesBeisswenger P, Makita Z, Curphey T, Moore L, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995, 44: 824-829. DOI: 10.2337/diabetes.44.7.824.
- Formation of Immunochemical Advanced Glycosylation End Products Precedes and Correlates With Early Manifestations of Renal and Retinal Disease in DiabetesBeisswenger P, Makita Z, Curphey T, Moore L, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H. Formation of Immunochemical Advanced Glycosylation End Products Precedes and Correlates With Early Manifestations of Renal and Retinal Disease in Diabetes. Diabetes 1995, 44: 824-829. PMID: 7789650, DOI: 10.2337/diab.44.7.824.
- Identification of the Major Site of Apolipoprotein B Modification by Advanced Glycosylation End Products Blocking Uptake by the Low Density Lipoprotein Receptor *Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the Major Site of Apolipoprotein B Modification by Advanced Glycosylation End Products Blocking Uptake by the Low Density Lipoprotein Receptor *. Journal Of Biological Chemistry 1995, 270: 10828-10832. PMID: 7738020, DOI: 10.1074/jbc.270.18.10828.
- Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathyNishino T, Horii Y, Shiiki H, Yamamoto H, Makita Z, Bucala R, Dohi K. Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy. Human Pathology 1995, 26: 308-313. PMID: 7890283, DOI: 10.1016/0046-8177(95)90063-2.
- An Inhibitor of Macrophage Arginine Transport and Nitric Oxide Production (CNI-1493) Prevents Acute Inflammation and Endotoxin LethalityBianchi M, Ulrich P, Bloom O, Meistrell M, Zimmerman G, Schmidtmayerova H, Bukrinsky M, Donnelley T, Bucala R, Sherry B, Manogue K, Tortolani A, Cerami A, Tracey K. An Inhibitor of Macrophage Arginine Transport and Nitric Oxide Production (CNI-1493) Prevents Acute Inflammation and Endotoxin Lethality. Molecular Medicine 1995, 1: 254-266. PMID: 8529104, PMCID: PMC2229913, DOI: 10.1007/bf03401550.
- A role for DNA mutations in diabetes-associated teratogenesis in transgenic embryosLee A, Plump A, DeSimone C, Cerami A, Bucala R. A role for DNA mutations in diabetes-associated teratogenesis in transgenic embryos. Diabetes 1995, 44: 20-24. DOI: 10.2337/diabetes.44.1.20.
- Conformational and disulfide bond analysis of macrophage migration inhibitory factor (MIF)Bernhagen J, Kapurniotu A, Stoeva S, Voelter W, Bucala R. Conformational and disulfide bond analysis of macrophage migration inhibitory factor (MIF). 1995, 572-573. DOI: 10.1007/978-94-011-1468-4_260.
- Different approaches for solid phase peptide synthesis of mouse macrophage migration inhibitory factorKaiser T, Bernhagen J, Bucala R, Paulus G, Voelter W. Different approaches for solid phase peptide synthesis of mouse macrophage migration inhibitory factor. 1995, 853-854. DOI: 10.1007/978-94-011-1468-4_393.
- Glucose as a Risk Factor for AtherosclerosisBucala R, Cerami A. Glucose as a Risk Factor for Atherosclerosis. 1995, 8: 155-163. DOI: 10.1007/978-94-011-0039-7_20.
- Advanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological InhibitionBucala R, Vlassara H. Advanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition. Blood Purification 1995, 13: 160-170. PMID: 7619388, DOI: 10.1159/000170199.
- A Role for DNA Mutations in Diabetes-Associated Teratogenesis in Transgenic EmbryosLee A, Plump A, DeSimone C, Cerami A, Bucala R. A Role for DNA Mutations in Diabetes-Associated Teratogenesis in Transgenic Embryos. Diabetes 1995, 44: 20-24. PMID: 7813809, DOI: 10.2337/diab.44.1.20.
- Identification of MIF as a new pituitary hormone and macrophage cytokine and its role in endotoxic shockBucala R. Identification of MIF as a new pituitary hormone and macrophage cytokine and its role in endotoxic shock. Immunology Letters 1994, 43: 23-26. PMID: 7737686, DOI: 10.1016/0165-2478(94)00152-9.
- Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue RepairBucala R, Spiegel L, Chesney J, Hogan M, Cerami A. Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair. Molecular Medicine 1994, 1: 71-81. PMID: 8790603, PMCID: PMC2229929, DOI: 10.1007/bf03403533.
- The primary site of apolipoprotein-B modification by advanced glycosylation endproducts (AGE-LDL) lies within a 28-kDa region located N-terminal to the LDL-receptor binding domainBucala R, Mitchell R, Vlassara H, Cerami A. The primary site of apolipoprotein-B modification by advanced glycosylation endproducts (AGE-LDL) lies within a 28-kDa region located N-terminal to the LDL-receptor binding domain. Atherosclerosis 1994, 109: 47. DOI: 10.1016/0021-9150(94)93201-8.
- MIF IS AN IMPORTANT MEDIATOR OF THE TOXIC SHOCK SYNDROME.Calandra T, Bernhagen J, Cerami A, Bucala R. MIF IS AN IMPORTANT MEDIATOR OF THE TOXIC SHOCK SYNDROME. Shock 1994, 2: 16. DOI: 10.1097/00024382-199409001-00007.
- Identification of 4-hydroxyhexenal as an oxidation product formed during LDL advanced glycosylationAl-Abed Y, Voelter W, Cerami A, Bucala R. Identification of 4-hydroxyhexenal as an oxidation product formed during LDL advanced glycosylation. Atherosclerosis 1994, 109: 57-58. DOI: 10.1016/0021-9150(94)93246-8.
- Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular diseaseBucala R, Vlassara H, Cerami A. Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular disease. Drug Development Research 1994, 32: 77-89. DOI: 10.1002/ddr.430320204.
- Macrophage migration inhibitory factor is a neuroendocrine mediator of endotoxaemiaBernhagen J, Calandra T, Cerami A, Bucala R. Macrophage migration inhibitory factor is a neuroendocrine mediator of endotoxaemia. Trends In Microbiology 1994, 2: 198-201. PMID: 8087451, DOI: 10.1016/0966-842x(94)90111-h.
- The emerging role of MIF in septic shock and infectionBernhagen J, Calandra T, Bucala R. The emerging role of MIF in septic shock and infection. Biotherapy 1994, 8: 123-127. PMID: 8924353, DOI: 10.1007/bf01878495.
- Comparative analysis of DNA mutations in lacI transgenic mice with ageLee A, Desimone C, Cerami A, Bucala R. Comparative analysis of DNA mutations in lacI transgenic mice with age. The FASEB Journal 1994, 8: 545-550. PMID: 8181674, DOI: 10.1096/fasebj.8.8.8181674.
- Differential expression of the small inducible cytokines GRO α and GROβ by synovial fibroblasts in chronic arthritis: Possible role in growth regulationHogan M, Sherry B, Ritchlin C, Fabre M, Winchester R, Cerami A, Bucala R. Differential expression of the small inducible cytokines GRO α and GROβ by synovial fibroblasts in chronic arthritis: Possible role in growth regulation. Cytokine 1994, 6: 61-69. PMID: 8003635, DOI: 10.1016/1043-4666(94)90009-4.
- Hemoglobin-AGE: A Circulating Marker of Advanced GlycosylationMakita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R. Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation. Science 1992, 258: 651-653. PMID: 1411574, DOI: 10.1126/science.1411574.
- Advanced Glycosylation: Chemistry, Biology, and Implications for Diabetes and AgingBucala R, Cerami A. Advanced Glycosylation: Chemistry, Biology, and Implications for Diabetes and Aging. 1992, 23: 1-34. PMID: 1540533, DOI: 10.1016/s1054-3589(08)60961-8.
- Fortgeschrittene Glykierung und die Pathogenese der diabetischen GefäßkomplikationenBucala R, Vlassara H, Cerami A. Fortgeschrittene Glykierung und die Pathogenese der diabetischen Gefäßkomplikationen. 1990, 1-14. DOI: 10.1007/978-3-642-75712-9_1.
- Labile T-wave changes caused by respiratory variation in a patient with unstable anginaBucala R, Loh E, Wang P, Rutherford J. Labile T-wave changes caused by respiratory variation in a patient with unstable angina. International Journal Of Cardiology 1988, 19: 260-262. PMID: 3372087, DOI: 10.1016/0167-5273(88)90087-3.
- Structure of lysine adducts with 16α-hydroxyestrone and cortisolBucala R, Ulrich P, Chait B, Bencsath F, Cerami A. Structure of lysine adducts with 16α-hydroxyestrone and cortisol. The Journal Of Steroid Biochemistry And Molecular Biology 1986, 25: 127-133. PMID: 3091937, DOI: 10.1016/0022-4731(86)90291-8.
- Determination of 16 alpha‐hydroxyestrone by radioimmunoassay in systemic lupus erythematosusLahita R, Bucala R, Bradlow H, Fishman J. Determination of 16 alpha‐hydroxyestrone by radioimmunoassay in systemic lupus erythematosus. Arthritis & Rheumatism 1985, 28: 1122-1127. PMID: 4052123, DOI: 10.1002/art.1780281007.
- Non‐enzymatic modification of proteins by steroids: Pathological implications for autoimmunity and glucocorticoid toxicityBucala R, Cerami A. Non‐enzymatic modification of proteins by steroids: Pathological implications for autoimmunity and glucocorticoid toxicity. BioEssays 1985, 3: 55-59. PMID: 3842583, DOI: 10.1002/bies.950030204.
- Glucocorticoid-lens protein adducts in experimentally induced steroid cataractsBucala R, Callati M, Manabe S, Cotlier E, Cerami A. Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts. Experimental Eye Research 1985, 40: 853-863. PMID: 4018168, DOI: 10.1016/0014-4835(85)90130-7.
- Increased levels of 16 alpha-hydroxyestrone-modified proteins in pregnancy and in systemic lupus erythematosus.BUCALA R, LAHITA R, FISHMAN J, CERAMI A. Increased levels of 16 alpha-hydroxyestrone-modified proteins in pregnancy and in systemic lupus erythematosus. The Journal Of Clinical Endocrinology & Metabolism 1985, 60: 841-7. PMID: 3920233, DOI: 10.1210/jcem-60-5-841.
- Role of Sex Steroids in Systemic Lupus Erythematosus (SLE)LAHITA R, BUCALA R, BRADLOW H, FISHMAN J. Role of Sex Steroids in Systemic Lupus Erythematosus (SLE). 1985, 33: 301-304. DOI: 10.1016/b978-0-08-033215-4.50074-1.
- Nonenzymatic modification of lens crystallins by prednisolone induces sulfhydryl oxidation and aggregate formation: In vitro and in vivo studiesBucala R, Manabe S, Urban R, Cerami A. Nonenzymatic modification of lens crystallins by prednisolone induces sulfhydryl oxidation and aggregate formation: In vitro and in vivo studies. Experimental Eye Research 1985, 41: 353-363. PMID: 4065253, DOI: 10.1016/s0014-4835(85)80026-9.
- The reaction of 16α‐hydroxyestrone with erythrocytes in vitro and in vivoBUCALA R, FISHMAN J, CERAMI A. The reaction of 16α‐hydroxyestrone with erythrocytes in vitro and in vivo. The FEBS Journal 1984, 140: 593-598. PMID: 6723653, DOI: 10.1111/j.1432-1033.1984.tb08143.x.
- Characterization of antisera to the addition product formed by the nonenzymatic reaction of 16α-hydroxyestrone with albuminBucala R, Cerami A. Characterization of antisera to the addition product formed by the nonenzymatic reaction of 16α-hydroxyestrone with albumin. Molecular Immunology 1983, 20: 1289-1292. PMID: 6656775, DOI: 10.1016/0161-5890(83)90159-1.
- Cytotoxicity of a Perfluorocarbon Blood Substitute to Macrophages in VitroBucala R, Kawakami M, Cerami A. Cytotoxicity of a Perfluorocarbon Blood Substitute to Macrophages in Vitro. Science 1983, 220: 965-967. PMID: 6844922, DOI: 10.1126/science.6844922.